













B.S., Yangzhou University, 2009 




AN ABSTRACT OF A DISSERTATION 
 
 








Department of Animal Sciences and Industry 














The transition period in dairy cows is characterized by dramatic increases in nutrient 
requirements for lactation and substantial metabolic stress. The disturbed metabolic balance, 
coupled with suppressed immune function, contributes to markedly elevated incidence of health 
disorders. Several lines of evidence suggest that increased inflammation is common during the 
transition period. Unlike the classical inflammation associated with acute infection, the 
postpartum inflammatory state is low-grade and often of metabolic origin. This metabolic 
inflammation plays a key role in numerous disorders; an improved understanding of 
inflammatory pathways in transition cows may improve our ability to predict and prevent 
disorders. To mimic metabolic inflammation, in Experiment 1, we administered low amounts of 
recombinant bovine tumor necrosis factor-α (rbTNFα), a pro-inflammatory cytokine, to early 
lactation cows, and evaluated whether rbTNFα affects milk production, metabolism, and health. 
We found that rbTNFα administration increased systemic inflammation, decreased feed intake 
and milk yield, and increased incidence of disorders. Conversely, preventing excessive 
inflammation has the potential to improve productivity and health of dairy cows. To identify 
nutritional strategies that could enhance metabolism and immunity, we evaluated the efficacy of 
several feed additives. In Experiment 2, we evaluated effects of chromium propionate, rumen-
protected lysine and methionine, or both on metabolism and immunity in lactating dairy cows, 
and found that supplementation of these nutrients may enhance neutrophil function. In 
Experiment 3, we determined whether supplementation of yeast product to transition cows could 
enhance production, metabolism, and immunity, and found that yeast product modulated feeding 
behavior, metabolism, immunity, and uterine inflammation. Overall, a greater understanding of 
the role of metabolic inflammation in the transition period and the nutritional strategies that 
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Chapter 1 - Literature Review 
 Introduction 
The transition from late gestation to early lactation is often the most problematic period 
in the production cycle of dairy cows. In an attempt to cope with dramatic nutrient and energy 
requirements for milk production, cows experience tremendous metabolic stress. The disturbed 
metabolic balance, coupled with suppressed immune fction around parturition, contributes to 
markedly elevated incidence of metabolic disorders and infectious diseases during this time. 
Therefore, the transition period directly determines the lactational performance, health, and 
profitability of dairy cows; it is critical to develop effective nutritional strategies that could 
enhance the metabolism and immunity of transition cws. 
Among other diseases, early-lactation cows experience particularly high rates of mastitis, 
metritis, displaced abomasum, ketosis, and fatty liver. Although these issues have been the focus 
of much research in recent decades, the etiology of these diseases is not completely understood. 
With the physiological stress and metabolic changes that accompany the processes of parturition 
and the initiation of lactation, increased inflammation is common during the postpartum period. 
Inflammation is known to play a major role in infectious diseases and recent research has 
suggested that it is involved in metabolic diseases as well. An improved understanding of the 
role of inflammatory pathways in early-lactation cows may improve our ability to prevent 
disorders. 
This literature review will first describe the characteristics of nutrient metabolism and 
immune function in transition dairy cows. It will then explore the roles of “classical” and 




metabolism, health, and production of transition cows. Finally, it will discuss several nutritional 
strategies that could potentially modulate the metabolism and immunity in dairy cows. 
 
 Characteristics of Transition Cows 
 1. Lipid Metabolism 
The transition from late gestation to early lactation is characterized by dramatic nutrient 
and energy requirements for milk synthesis and secretion, substantial metabolic stress, and 
endocrine changes. In the meantime, feed intake is often depressed, leading to negative energy 
balance status (Grummer, 1995). In responses to the energy deficit, cows mobilize adipose 
tissue, resulting in dramatic elevation of non-esterified fatty acid (NEFA) concentrations in the 
blood. The liver takes up the high flux of blood NEFA and often exceeds its capacity to 
completely oxidize NEFA to CO2, resulting in partial oxidation to form ketones or esterification 
to form triglyceride (TG) within hepatocytes (Grummer, 2008). Excessive production and 
accumulation of ketones often lead to ketosis, which is characterized by elevated blood 
concentrations of β-hydroxybutyrate (BHBA), depressed appetite, and decreased milk production 
(Oetzel, 2007). Furthermore, because ruminants are inefficient at exporting TG out of the liver, 
excessive TG accumulation or fatty liver occurs. Ketosis and fatty liver affect up to 50% of dairy 
cows, compromising health and production (Bobe et al., 2004; Oetzel, 2007). These health issues 
are also associated with increased incidence of multiple other disorders or diseases, including 
displaced abomasum, mastitis, and metritis, which together create a costly epidemic of transition 




has been extensively studied, the mechanisms underlying the development of these metabolic 
disorders are not fully understood. 
 
 2. Glucose Metabolism 
In response to metabolic demands of lactation, the requirements for glucose increase 
dramatically during the transition period. For example, estimated glucose demand is 
approximately 1 kg/d during the last 21 d of gestation, but increases dramatically after parturition 
to approximately 2.5 kg/d at 21 d postpartum (Overton, 1998). Most of this increased glucose 
requirement must be met via hepatic gluconeogenesis, wh ch is of great importance in ruminants 
at all times, providing the majority of necessary glucose (Young, 1977). Simultaneously, as part 
of the homeorhetic adaptation, glucose oxidation by peripheral tissues is decreased (Bennink et 
al., 1972) to direct glucose to the mammary gland for lactose synthesis. The primary substrate to 
support gluconeogenesis is propionate from ruminal fermentation; yet because early-lactation 
cows often experience inadequate feed intake, meeting glucose needs can be a tremendous 
challenge. Besides propionate, other substrates contributing to gluconeogenesis include lactate 
from Cori cycling, amino acids from protein catabolism or net absorption, and glycerol released 
from adipose tissue mobilization (Seal and Reynolds, 1993). The contributions to net liver 
glucose release have been estimated to be from 50 to 6 % for propionate, 20 to 30% for amino 
acids, and only 2 to 4% for glycerol during the transition period (Reynolds et al., 2003). Cows 
adapt to early lactation by increasing the capacity and efficiency of glucose synthesis from 
multiple substrates. For example, compared with d 21 prepartum, propionate conversion to 




hepatic capacity to convert [1-14C] alanine to glucose was approximately doubled immediately 
postpartum (Overton et al., 1998).  
Metabolic disorders, particularly fatty liver and ketosis, have been associated with 
decreased gluconeogenesis (Cadorniga-Valino et al., 1997; Veenhuizen et al., 1991), but there is 
no clear mechanism explaining this association. Based on the evidence that inflammatory 
cytokines, such as tumor necrosis factor α (TNFα), can promote liver fat accumulation (Feldstein 
et al., 2004) and alter gluconeogenesis (da Rocha et al., 2013), we hypothesized that 
inflammatory signals may link fatty liver to decreas d glucose production in dairy cows. In fact, 
our previous research found that TNFα infusion induced liver TG accumulation and reduced 
liver gluconeogenic gene expression in late-lactation cows (Bradford et al., 2009), but the effect 
of TNFα administration on liver glucose production per se was not assessed. If inflammatory 
cytokines impair glucose production in early-lactation cows or those with naturally occurring 
fatty liver, the resulting glucose deficiency would likely further increase adipose mobilization 
and exacerbate metabolic disorders. 
 
 3. Immunosuppression 
Infectious diseases reduce profitability through decreased production efficiency and 
increased morbidity and mortality. Mastitis has been reported to reduce whole-lactation milk 
yield by almost 600 kg (Rajala-Schultz et al., 1999), and is also an important risk factor for 
involuntary culling (Gröhn et al., 1988). Risk of in ections of the mammary gland (mastitis) or 
uterus (metritis) increases dramatically during the transition period. Although the etiologies of 
infectious and metabolic disorders differ, there was a significant association between their 




(Curtis et al., 1985), suggesting that there are pot ntial interactions between transition cow 
metabolism and immune function. 
The increased incidence and severity of diseases in the transition period are partially due 
to suppressed immune function, or immunosuppression. This immune dysfunction is broad in 
scope and affects multiple functions of various immune cell types. When E. coli were 
administered into the mammary gland, transition cows experienced more rapid bacterial growth 
and greater bacterial concentrations compared with mid-lactation cows (Shuster et al., 1996). 
Among other immune cells, neutrophils are the firstl ne of immune defense, and decreased 
neutrophil function is a main characteristic of impaired immunity in transition cows. Upon 
maturation in bone marrow, neutrophils are released into circulation and perform key functions 
for successful immune surveillance and defense against pathogens, including margination, 
migration, phagocytosis, respiratory burst, and degranulation (Burton and Erskine, 2003). Each 
of these steps must work rapidly and effectively to clear infections. For example, impaired 
margination and migration may partially explain neutrophil dysfunction in early-lactation cows. 
Circulating neutrophils use adhesion molecules, such as L-selectin, for vascular margination. 
Kimura et al. (1999) reported that expression of L-selectin on neutrophils was dramatically 
decreased at calving, correlating well with the surge of blood cortisol, a potent 
immunosuppressive hormone. This reduced L-selectin xpression would inhibit neutrophil 
margination and depress neutrophil recruitment into mammary glands of newly calved cows, 
increasing the risk of mastitis. Other studies have reported that compared with blood neutrophils 
isolated from mid-lactation or late-lactation cows, neutrophils in early-lactation cows have 
decreased ability to generate reactive oxygen species following phagocytosis of opsonized 




phagocytosis, and killing may directly contribute to immunosuppression and increased disease 
incidence in transition cows (Kehrli et al., 1989).  
The cause of immunosuppression in the transition period is not completely understood, 
but is related to endocrine and metabolic factors. For example, elevated glucocorticoids around 
parturition are partially responsible for immunosuppression (Burton et al., 1995). Also, changes 
in estradiol and progesterone concentrations prior to calving may affect immune function (Weber 
et al., 2001). Kimura and colleagues (1999) reported that compared with mastectomized cows, 
the presence of the mammary gland and its subsequent metabolic demands slowed recovery of 
neutrophil function postpartum, suggesting that metabolic factors associated with lactation 
exacerbated immunosuppression. Negative energy balance may also contribute to immune 
dysfunction. In fact, markers associated with energy deficiency, including NEFA and ketones, 
have been implicated in impaired immunity. Concentrations of NEFA similar to that reported in 
transition cows, decreased neutrophil respiratory bu st activity in vitro (Ster et al., 2012). Field 
studies also suggest that elevated NEFA and ketones around parturition increase the risk of 
clinical mastitis, displaced abomasum, metritis, and retained placenta (Moyes et al., 2009; 
Ospina et al., 2010). 
 
 Inflammation 
 1. Classical Inflammation 
Underlying many physiological and pathological processes, inflammation is an adaptive 
response that is triggered by adverse stimuli and co itions, such as infection and tissue injury 




pain. In response to inflammatory stimuli, the body ften increases the release or expression of 
inflammatory mediators that are critical for both vascular changes and leukocyte infiltration 
(Newton and Dixit, 2012). Some of the key mediators released by activated immune cells include 
cytokines, chemokines, adhesion molecules, eicosanoids, and plasma proteins. These molecules 
form complex regulatory networks and promote increased blood flow to the infected tissue and 
immune cell infiltration and activation, and they also stimulate systemic responses, including 
increased body temperature, increased heart rate, and decreased appetite (Dantzer and Kelley, 
2007). Cytokines such as TNFα, interleukin (IL) 1β, and IL-6 are produced by many cell types, 
especially by macrophages and mast cells. They play important roles in the inflammatory 
response, including activation of the endothelium and leukocytes and induction of the acute-
phase response (Bannerman, 2009). Eicosanoids represent another class of inflammatory 
mediators. They are fatty acid-derived molecules exerting complex control over inflammation, 
and can either enhance (such as certain types of prostaglandins, prostacyclins, thromboxanes, 
and leukotrienes) or resolve (such as resolvins, protectins, and maresins) inflammatory response 
depending on their types and timing of expression (Sordillo et al., 2009).  
In dairy cows, the most costly inflammatory disease is mastitis, which commonly results 
from microbial infection of the mammary gland (Bannerman et al., 2009). If the infection is 
caused by Gram-negative bacteria, lipopolysaccharide (LPS) released from the bacteria outer 
membrane is the main pathogen component initiating inflammatory responses (Hogan and Smith, 
2003). At the initiation of immune response, the ligat on of LPS to toll-like receptor (TLR) 4 
initiates a signal transduction pathway that activates a complex cascade of inflammatory 
mediators released by host immune and epithelial cells (Ballou, 2012; Erskine, 1995). The TLR4 




which is considered the master regulator of inflammation controlling the expression of hundreds 
of immune-associated genes (Ghosh and Hayden, 2008). Activated NF-κB subsequently enters 
the nucleus and bind to target promoters, orchestrating the synthesis of a whole battery of 
inflammatory genes (Akira and Takeda, 2004). In mastitis, the production of pro-inflammatory 
cytokines, including IL-1β, IL-6, IL-8, and TNFα, are increased by LPS in an NF-κB dependent 
manner (Schukken et al., 2011). These cytokines, together with other inflammatory mediators, 
elicit the migration of leukocytes (primarily neutrophils) to the site of infection (i.e. mammary 
gland). Once they reach the afflicted tissue, neutrophils become activated and release the toxic 
contents of their granules, including reactive oxygen species, reactive nitrogen species, 
proteinase, and elastase. These highly potent effectors are important to facilitate the clearance of 
pathogens, but they may also promote the breakdown of blood-milk barrier and induce mammary 
epithelial tissue damage (Schukken et al., 2011). The reduced number and activity of secretory 
cells consequently contribute to decreased milk synthesis and secretion (Schukken et al., 2011). 
Cytokines can also directly elicit pro-inflammatory signals by binding to their receptors. 
For example, in response to TNFα, TNF receptor-1 (TNFR1) and TNFR2 are activated, lading 
to the activation of several distinct signaling pathways, including NF-κB, activator protein 1 
(AP-1), and Caspases pathways (Baud and Karin, 2001). In the initiation of NF-κB signaling, 
TNFR-associated death domain (TRADD) binds to TNFR1, and recruits TNF receptor-
associated factor 2 (TRAF2) and receptor-interacting ki ase (RIP). TRAF2 in turn recruits and 
eventually activates inhibitor of NF-κB kinase (IKK). In nonstimulated cells, NF-κB is bound to 
an inhibitory protein IκBα and sequestered in the cytoplasm. In the activation pr cess, IκBα is 
phosphorylated by IKK and then degraded; subsequently, the liberated NF-κB is translocated to 




proliferation, and inflammatory responses (Wajant et al., 2003; Häcker and Karin, 2006). 
Stimulation of TNFR1 can also lead to a strong activ tion of the apoptotic pathway, and there is 
increasing evidence that the NF-κB and the apoptotic pathway are tightly connected (Wajant et 
al., 2003). Furthermore, TNFα can induce strong activation of the stress-related c-Jun N-terminal 
kinase (JNK) group and the p38- mitogen-activated protein kinase (p38-MAPK). These 
pathways are also involved in cell differentiation, proliferation, apoptosis, stress, and 
inflammation (Wajant et al., 2003). The precise pathways of TNFα signaling have not been 
described in bovine diseases. 
In addition to mastitis, infection of the uterus is al o common in the early-lactation 
period. Essentially all cows have bacterial contamination of the uterus within 3 wk after calving, 
and the majority of them have at least one form of pathology of the reproductive tract (LeBlanc 
et al., 2011). Metritis is a severe inflammatory reaction (often occurs with the first week of 
lactation) involving all layers of the uterus, resulting in systemic signs of sickness, including 
fever, watery foul-smelling uterine discharge, and low milk production (LeBlanc, 2008). 
Endometritis is the inflammation of uterus surface epithelium without systemic illness, occurring 
later than 3 wk postpartum. Histologically, endometritis is characterized by disruption of the 
endometrial epithelium, inflammatory cell infiltration, and vascular congestion (LeBlanc, 2008).   
Although a controlled inflammatory process normally leads to recovery from infection, a 
dysregulated (such as septic shock) or chronic inflammatory condition can also be detrimental. 
Therefore, in an ideal acute inflammatory response, a rapid resolution phase following the 





 2. Metabolic Inflammation  
Although inflammation is part of the protective host response to infection and injury, 
inappropriate inflammation leads to many adverse outcomes. Indeed, systemic low-grade chronic 
inflammation occurs in a wide variety of diseases, including obesity and type 2 diabetes. The 
chronic inflammation associated with metabolic disorders is also referred to as metabolic 
inflammation (Hotamisligil, 2006). In contrast to classical inflammation that is induced by 
infection and injury, metabolic inflammation seems to be associated with tissue malfunction. In 
light of the world epidemic of obesity, extensive research has been conducted to explore the role 
of metabolic inflammation in this disorder. Therefore, I will use obesity as an example to 
describe the characteristics of metabolic inflammation. In obesity, metabolic inflammation is 
orchestrated by metabolic cells in response to excess nutrients and energy, and the hallmarks are 
as follows (Gregor and Hotamisligil, 2011). 
First, this inflammatory response is induced by nutrien  signals and orchestrated by 
metabolic tissues (such as adipocytes, liver, pancreas, and brain), and in turn impairs metabolic 
homeostasis. Research demonstrated that an array of inflammatory cytokines, including TNFα, 
IL-6, IL-1β, and others are increased in obese adipose tissues (Hotamisligil et al., 1995; Shoelson 
et al., 2006). Second, the response is low-grade; in contrast to the acute inflammation observed 
in infection, the elevated inflammatory responses in metabolic tissues are often modest and local. 
Third, it creates an environment with modified composition of immune cells promoting a 
proinflammatory status. For example, one key feature of obesity is increased infiltration of 
macrophage into the adipose tissues. Compared with the lean state, there is a 5-fold increase in 
adipose tissue macrophage content in the obese state, with macrophages constituting up to 50% 




an anti-inflammatory M2 type to a proinflammatory M1 type, which in turn decrease insulin 
sensitivity (Olefsky and Glass, 2010). Emerging evid nce suggests that the profiles of other 
immune cells, including B and T lymphocytes, mast cells, and natural killer T cells, are also 
altered in obese adipose tissues (Johnson et al., 2012; Liu et al., 2009; Ohmura et al., 2010), 
creating an environment favorable to immune activation. These data indicate that multiple types 
of immune cells are involved in the response to the metabolic stress, together leading to 
metabolic pathophysiology. Fourth, it is a chronic state without clear resolution. In contrast to 
acute inflammation where rapid response and resolution occur, metabolic inflammation appears 
to develop gradually and remain unresolved.  
It is known that in classical inflammatory responses, pathogens often engage a cell 
signaling pathway to initiate an immune response. How is metabolic inflammation initiated? 
Although the initiating factor of this inflammation is not completely clear, metabolic cells seem 
to be capable of engaging inflammatory signaling in response to abnormal signals (Gregor and 
Hotamisligil, 2011). For example, excess nutrients i  obesity can engage the pathogen-sensing or 
immune response pathways, such as TLR and NF-κB signaling, to produce cytokines in response 
to metabolic stress signals (Gregor and Hotamisligil, 2011). Specifically, the roles of 
glucotoxicity, lipotoxicity, stress kinases, and endoplasmic reticulum stress in shaping the 
immune response in adipose tissue were all highlighted in recent research (Johnson et al., 2012). 
In summary, metabolic inflammation represents a low-grade chronic inflammatory 
response initiated by excess nutrients in metabolic cells. This response eventually activates 
multiple types of immune cells and leads to an unresolved tissue inflammatory response. This 
inflammatory response often disrupts metabolism by mechanisms such as inhibiting insulin 




and homeostasis. In the case of transient abnormal conditions, a successful acute inflammatory 
response often provides benefits; however, if the abnormal conditions are sustained, the response 
can become maladaptive.  
 
 3. Inflammatory Status in Transition Cows 
With the physiological stress and metabolic changes that accompany the processes of 
parturition and the initiation of lactation, increased inflammation is common during the 
postpartum period. Unlike the inflammation associated with acute infection, the postpartum 
inflammatory state is often low-grade without the classical signs of inflammation, consistent 
with the concept of metabolic inflammation (Hotamisligil, 2006). A recent study (Sabedra, 2012) 
using 161 transition cows found that serum acute phase protein haptoglobin was elevated around 
parturition, even in cows that were apparently healt y; cows that experienced diseases or calving 
difficulties had significantly greater concentrations compared with healthy animals. In addition 
to increased haptoglobin in the serum, evidence suggests that the mRNA or protein abundance of 
haptoglobin was also increased in liver and adipose tis ue in the first week of lactation (Saremi et 
al., 2012), indicating elevated inflammatory signals postpartum are often systemic and not 
limited to a specific focal organ.  
The association between inflammation and bovine metabolic diseases is well established. 
Ametaj et al. (2005) reported that plasma concentrations of inflammatory markers, including 
haptoglobin and serum amyloid A, were elevated in cows that developed fatty liver; plasma 
TNFα concentration prior to parturition was positively related to postpartum liver lipid 
concentration. Similarly, Ohtsuka et al. (2001) observed increased serum TNFα activity in cows 




evaluated direct effects of inflammation on metabolic function. Oral administration of interferon-
α daily during the last 2 wk prepartum increased markers of inflammation and plasma ketone 
concentrations postpartum (Trevisi et al., 2009). Subcutaneous injection of low dose TNFα for 7 
days increased liver TG content by 2-fold in late-lactation dairy cows (Bradford et al., 2009). 
The changes in the patterns of gene expression in the liver were also consistent with the increase 
in fatty acid uptake and storage, and a decrease in fatty acid oxidation. These data indicate that 
inflammation disrupts metabolism, and may be a mechanism underlying the development of fatty 
liver.  
Inflammation may negatively impact production. By measuring a panel of inflammatory 
markers and separating transition cows into quartiles for degree of inflammation, Bertoni et al. 
(2008) reported cows in the highest quartile had significantly lower (by 20%) milk yields than 
those in the lowest quartile throughout the first month of lactation. Similarly, postpartum plasma 
concentrations of haptoglobin greater than 1.1 g/L were associated with 947 kg decrease in 305-
day mature equivalent milk yield (Huzzey et al., 201 ). These data seem to be consistent with the 
concept that in response to inflammation, which is often associated with decreased energy intake, 
cows divert resources away from milk production andtoward survival (Ballou, 2012). On the 
other hand, several studies showed that anti-inflamm tory treatments improved long-term 
production. Trevisi and Bertoni (2008) found that aspirin treatment over the first 5 d postpartum 
increased milk yield through the first 60 d of lactation, with a 13% increase in peak milk yield. 
Our laboratory recently reported that administration of sodium salicylate (123 g/cow daily) via 
individual water bowls during the first 7 d postpartum increased 305-d milk yield by 2,469 kg 
(21% increase) and milk fat by 130 kg (30% increase) in ≥3rd parity cows compared with the 




Despite the potential harmful effects of inflammation, certain amounts of inflammation 
may be necessary to facilitate the adaptation of metabolic and physiological changes in the 
transition period. Perhaps the most well known aspect of inflammation is its role in clearance of 
pathogens and resolution of infections. Given that e incidence of infections increases 
dramatically in early lactation, activation of inflammatory pathways may help cows fight off 
diseases. One key mechanism to support copious milk synthesis and secretion in dairy cows is 
insulin resistance, which diverts the nutrients away from peripheral adipose tissue and muscle to 
the mammary gland (Bell, 1995). The mechanisms initiating this adaptive insulin resistance in 
early lactation are not clear. Because inflammation of muscle and adipose tissue is tightly linked 
to insulin resistance in many metabolic scenarios (Odegaard and Chawla, 2013), it is possible 
that endogenous inflammation in early lactation is eeded to promote insulin resistance as 
nutrient demands for the mammary gland increase. Another key role of inflammation in the 
transition cow is to facilitate calving. Parturition is characterized by a massive influx of 
macrophages and neutrophils into the myometrium; this proinflammatory environment promotes 
the dilation of the cervix, contraction of the uterus, rupturing the fetal membranes, and expulsion 
of the placenta (Challis et al., 2009).  
Taken together, inflammation plays a crucial role in mammalian physiological and 
pathological functions. An increased inflammatory state is common in transition dairy cows. 
This mild inflammation may support the cow’s ability to fight against infection, redistribute 
glucose for lactation, and facilitate the process of parturition. On the other hand, excessive 
inflammation may decrease feed intake, exacerbate me abolic imbalances, promote health 




necessary to identify and promote a healthy degree of inflammation while minimize the 
pathological aspects of inflammation in transition cows. 
 
 Nutritional Strategies to Modulate Metabolism and Immunity 
 1. Chromium 
Chromium (Cr) is an essential nutrient that modulates metabolism. Supplementation of 
Cr in cattle increased milk production (Hayirli et al., 2001; McNamara and Valdez, 2005; Smith 
et al., 2005), improved glucose clearance and insuli  ensitivity (Bunting et al., 1994; Spears et 
al., 2012; Sumner et al., 2007), reduced lipolysis (Besong, 1996; Bryan et al., 2004), altered 
adipose tissue metabolism (McNamara and Valdez, 2005), and modulated immune response 
(Burton et al., 1993; Burton, 1995; Burton et al., 1996). Most studies evaluating effects of Cr 
supplementation on dairy cattle metabolism have been conducted in the transition period. Hayirli 
et al. (2001) reported that supplementing cows with0, 0.03, 0.06, and 0.12 mg/kg BW0.75 of Cr 
as chromium-L-methionine (Cr-Met) from 21 d prepartum to 28 d postpartum did not affect 
prepartum plasma glucose or glucagon concentrations, but increased insulin and decreased 
NEFA. After parturition, none of these measures wasaffected by Cr except for decreased plasma 
insulin. Smith et al. (2008) reported that supplementation of 0.03 mg/kg BW0.75 of Cr as Cr-Met 
increased prepartum plasma glucose and glucagon concentrations, and tended to decrease 
prepartum plasma NEFA concentrations compared with either 0 or 0.06 mg of Cr/kg of BW0.75; 
these metabolites were unaffected by Cr postpartum. By feeding Cr-propionate (CrPr) to dairy 
cows from 21 d prepartum to 35 d postpartum, McNamar  and Valdez (2005) increased dry 




dramatically increased adipose tissue lipogenesis compared to that of controls in the postpartum 
period. Collectively, these results indicate that CrPr may improve production by modulating 
metabolism of lactating cows. 
One important characteristic of Cr is its modulatory effect on insulin sensitivity. It is 
established that Cr supplementation alleviates insulin resistance, enhances glucose tolerance, and 
improves metabolism in obese or type 2 diabetic subjects (Cefalu et al., 2010; Kim et al., 2011a; 
Wang and Cefalu, 2010). Although the mode of action is ot precisely known, Cr has been 
shown to enhance insulin binding, insulin receptor abundance, and pancreatic β- ell sensitivity 
(Wang and Cefalu, 2010). In dairy cows, there has been interest in effects of Cr supplementation 
on insulin sensitivity in the transition period (Sano et al., 1993), when insulin resistance typically 
occurs (Bell and Bauman, 1997). Subiyatno et al. (1996) found that supplementation of 0.5 mg 
Cr/kg dry matter beginning 6 wk prepartum increased insulin sensitivity in primiparous but not 
multiparous dairy cows at 2 wk before parturition. Hayirli et al. (2001) reported that Cr-Met 
supplementation from 21 d prepartum to 28 d postpartum improved glucose tolerance and insulin 
responsiveness measured at 28 d postpartum in multiparous dairy cows. Therefore, by 
modulating insulin action, Cr may have significant implications for health and production of 
dairy cows.  
Several studies have highlighted the role of Cr in bovine immunity. Burton et al. (1993) 
reported that Cr supplementation at 0.5 mg Cr/kg dry matter from 6 wk prepartum through 16 wk 
postpartum increased antibody responses to ovalbumin administration and mitogen-stimulated 
blastogenesis of blood monocytes in lactating cows. In addition, TNFα and IL-2 production from 
mitogen-stimulated monocytes was significantly decreased for cows supplemented with Cr 
compared with controls, particularly around peak lactation (Burton et al., 1996). Together, these 
 
results suggest that supplemental Cr may modulate immune function and metabolism of dairy 
cows. 
 
 2. Yeast Product 
Yeasts are unicellular fungi known for the ability to ferment sugars for the production of 
ethanol. The most commercially significant yeasts are 
organisms have long been used to ferment starch to produce alcoholic beverages and in the 
baking industry to expand, raise, or dough (Schneiter, 2004). In humans, yeast is often taken as a 
nutritional supplement because it is an excellent so
2004). In ruminants, yeast (Saccharomyces cerevisiae
in an attempt to improve ruminal fermentation, feed intake, and milk yield. Dann et al. (2000) 
reported that yeast cult re supplementation at 60 g/d from 21 d prepartum to 140 d postpartum 
improved dry matter intake during both the last 7 d prepartum (9.8 vs. 7.7 kg) and the first 42 d 
of lactation (13.7 vs. 11.9 kg) in Jersey cows. In addition, compared with control anim
supplemented with yeast culture reached peak milk production more quickly. The effects of yeast 
product supplementation on intake, production, and rumen fermentation characteristics were 
inconsistent among different studies. Desnoyers et al. (200
analysis using 157 experiments to assess the responses 
yeast product supplementation increased rumen pH (+0.03), total
digestibility (+0.8%), dry matter intake 
of body weight), and tended to increase milk fat content (+0.05%). These results indicate that 
yeast supplementation may modulate the metabolism and improve the production of dairy cows.
 17
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Recent findings suggest yeast products may enhance immune function. Kim et al. 
(2011b) reported that neonatal calves fed hydrolyzed yeast had enhanced acute phase response, 
antibody production, and health scores when challenged with live vaccines, compared with 
control. Such responses are often attributed either to improved energy status via effects on 
digestive function or on activation of the immune system through cell sensing of yeast 
components in the gut. One overlooked aspect of the response to yeast is the potential to 
specifically influence mucosal immunity. Mucosal surfaces of the intestinal, respiratory, and 
urinary tracts are the most common route of entry of microbial pathogens into the host. Epithelial 
cells that line mucosal surfaces are important mechani al barriers to prevent most microbes 
found in the environment, including commensal microbes, from entering epithelial cells 
(Kagnoff and Eckmann, 1997). Indeed, production and secretion of immunoglobulin A (IgA) 
into the gut lumen provide the “first line of defense” against enteric pathogens by preventing 
colonization of the mucosal surface (Winner et al., 1991). A recent study (Zanello et al., 2011) 
found that yeast modulated gene expression involved in inflammation and immune cell 
activation in porcine intestinal epithelial cells. Specifically, yeast decreased the expression of 
pro-inflammatory transcripts and proteins (including IL-6 and IL-8) induced by E. coli. 
In summary, interest in yeast products for dairy cows has expanded beyond a focus on 
altering ruminal fermentation and improving production. There are intriguing data suggesting 
that dietary yeast can improve energy status and immune function, particularly during 
physiological challenges. This raises the possibility that yeast supplementation can be used to 





 3. Bioactive Fatty Acids 
Bioactive fatty acids are important for the normal physiological functions and health of 
humans and domestic animals. As a class of long-chain fatty acids, omega-3 fatty acids include 
α-linolenic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), which are 
known to suppress inflammatory pathways. A number of recent studies have evaluated the use of 
flaxseed or fish oil-derived products to increase dietary supply of omega-3 fatty acids. Lessard et 
al. (2003) reported that feeding transition cows with flaxseed (a source of α-linolenic acid) 
increased serum omega-3 fatty acid concentration; on d 5 postpartum, the lymphocyte 
proliferative response of cows fed flaxseed was reduc  compared with cows received omega-6 
fatty acid supplements, suggesting an anti-inflammatory effect was achieved. On the other hand, 
Thatcher and colleagues have attempted to promote imune function in the transition period by 
supplementing calcium salts of omega-6 fatty acids instead of omega-3 fatty acids. Increasing the 
ratio of omega-6 to omega-3 fatty acids increased th  production of hydrogen peroxide and 
phagocytosis of bacteria by neutrophils, and also increased plasma concentrations of acute phase 
proteins (Silvestre et al., 2011). Although an increased neutrophil function may improve the 
ability of immune system to fight off infection, elevated acute phase protein markers may also 
indicate metabolic inflammation, which could possibly impair metabolic function (Bertoni et al., 
2008; Bradford et al., 2009). Therefore, further studies are needed to investigate if such an 
approach would benefit the clinical outcomes of transition cows.  
In addition to dietary fatty acid supplementation, the profiles of blood NEFA may also 
greatly impact immunity and metabolism. Increasing evidence suggests that transition cows 
experience not only elevated blood NEFA concentrations but also modified NEFA compositions. 




monounsaturated oleic acid are the predominant lipids in plasma NEFA, whereas there is a 
decrease in EPA and DHA (Sordillo and Raphael, 2013). These NEFA compositional changes 
can directly influence the fatty acid profiles of immune cells (Contreras et al., 2010), which may 
in turn alter immune function. For example, saturated fatty acids can enhance proinflammatory 
pathways through the activation of NF-κB (Kennedy et al., 2009). Conversely, EPA and DHA 
possess potent anti-inflammatory effects by activating G protein-coupled receptor 120 (Oh et al., 
2010). In addition, changes in NEFA composition could affect immunity by modifying the 
profile of eicosanoids produced. In general, eicosan ids generated from omega-6 fatty acids tend 
to promote inflammation, and those derived from omega-3 fatty acids tend to promote the 
resolution of inflammation (Serhan, 2009). Therefor, strategies that can modify blood lipid 
concentrations and composition, such as bioactive fatty acid supplementation, may also modulate 
the immunity and metabolism of dairy cows. 
 
 Conclusions 
The transition period in dairy cows is characterized by dramatic nutrient and energy 
requirements for lactation, substantial metabolic stres , and negative energy balance. In an 
attempt to adapt to the metabolic demands, cows increase lipid mobilization and hepatic 
gluconeogenesis. Inadequate adaptation is often associ ted with metabolic disorders, such as 
fatty liver and ketosis. Partially because of the disturbed endocrine and metabolic balance, the 
immune function in transition dairy cows is suppressed, leading to increased incidence of 
infectious diseases. Therefore, effective nutritional strategies that could enhance the metabolism 




With the metabolic stress and changes that accompany the processes of calving and the 
initiation of lactation, increased inflammation is common during the postpartum period. 
Inflammation plays a major role in infectious diseas and has been suggested to be involved in 
metabolic diseases as well. An improved understanding of the role of inflammatory pathways in 
early lactation cows may improve our ability to prevent disorders. 
The overall objectives of this dissertation were 1) to explore the impact of low-grade 
metabolic inflammation on metabolism, health, and production in early-lactation cows, and 2) to 
investigate nutritional strategies that could potentially modulate immunity and metabolism. In 
Experiment 1 (Chapter 2), we tested whether exogenous TNFα administration promotes 
inflammation, impairs glucose and lipid metabolism, and affects milk production and health in 
early-lactation dairy cows. In Experiment 2 (Chapter 3), we evaluated the effects of 
supplemental chromium propionate and amino acids on nutrient metabolism and neutrophil 
activation in lactating dairy cows. In Experiment 3 (Chapter 4 and 5), we determined the effects 
of yeast product supplementation on milk production, feeding behavior, metabolism, immunity, 
and uterine inflammation in transition dairy cows. A greater understanding of the role of 
inflammation in the transition period and the nutritional strategies that could modulate immunity 
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Inflammation may be a major contributing factor to peripartum metabolic disorders in 
dairy cattle. We tested whether administering an inflammatory cytokine, recombinant bovine 
tumor necrosis factor-α (rbTNFα), affects milk production, metabolism, and health during this 
period. Thirty-three Holstein cows (9 primiparous and 24 multiparous) were randomly assigned 
to 1 of 3 treatments at parturition. Treatments were 0 (Control), 1.5, or 3.0 µg/kg body weight 
rbTNFα, which were administered once daily by subcutaneous injection for the first 7 days of 
lactation. Statistical contrasts were used to evaluate the treatment and dose effects of rbTNFα 
administration. Plasma TNFα concentrations at 16 h post-administration tended to be increased 
(P < 0.10) by rbTNFα administration, but no dose effect (P > 0.10) was detected; rbTNFα 
treatments increased (P < 0.01) concentrations of plasma hptoglobin. Most plasma eicosanoids 
were not affected (P > 0.10) by rbTNFα administration, but 6 out of 16 measured eicosanoids 
changed (P < 0.05) over the first week of lactation, reflecting elevated inflammatory mediators in 
the days immediately following parturition. Dry matter and water intake, milk yield, and milk fat
and protein yields were all decreased (P < 0.05) by rbTNFα treatments by 15 to 18%. 
Concentrations of plasma glucose, insulin, β-hydroxybutyrate, non-esterified fatty acids, 
triglyceride, 3-methylhistidine, and liver triglyceride were unaffected (P > 0.10) by rbTNFα 
treatment. Glucose turnover rate was unaffected (P = 0.18) by rbTNFα administration. The 
higher dose of rbTNFα tended to increase the risk of cows developing one or more health 
disorders (P = 0.08). Taken together, these results indicate that administration of rbTNFα daily 
for the first 7 days of lactation altered inflammatory responses, impaired milk production and 











The periparturient period in dairy cows is characterized by substantial metabolic stress, 
endocrine changes, depressed feed intake, and negative energy balance (Grummer, 1995). In 
response to these changes, dairy cows mobilize adipose tissue triglyceride (TG), leading to 
elevated non-esterified fatty acid (NEFA) concentrations in the blood. The high flux of blood 
NEFA to the liver often exceeds the capacity of the liv r to completely oxidize NEFA to CO2, 
resulting in partial oxidation to form ketones or esterification to form TG within hepatocytes 
(Grummer, 2008). Excessive production of ketones often leads to ketosis, which is characterized 
by elevated blood concentrations of β-hydroxybutyrate (BHBA), depressed appetite, and 
decreased milk production (Oetzel, 2007). Furthermore, because ruminants are inefficient at 
exporting TG from the liver, excessive TG accumulation or fatty liver occurs. Ketosis and fatty 
liver affect up to 50% of dairy cows, compromising production, health, and reproduction (Oetzel, 
2007; Bobe et al., 2004). Gluconeogenesis is of great importance at all times in ruminants, 
providing up to 90% of the necessary glucose (Young, 1977). Meeting glucose needs can be a 
tremendous metabolic challenge for early-lactation dairy cows, which often experience 
inadequate feed intake. Although lipid and glucose metabolism in periparturient cows has been 
extensively studied, the mechanisms underlying the development of these metabolic disorders 
are not fully understood. 
Inflammatory mediators play critical roles in immunity and metabolism, and recent 
research has suggested that inflammation is involved in metabolic disorders as well. For 
example, obesity is associated with a chronic low-grade inflammatory state in multiple metabolic 
tissues including adipose, liver, muscle, pancreas, and brain (Gregor and Hotamisligil, 2011). 




factor-α (TNFα), a potent cytokine capable of triggering inflammatory responses (Hotamisligil et 
al., 1995). In dairy cows, fatty liver was associated with increased plasma inflammation markers, 
including haptoglobin and serum amyloid A (Ametaj et al., 2008). Although a recent study 
reported that plasma concentrations of TNFα in periparturient cows were decreased postpartum 
compared with prepartum (Schoenberg et al., 2011), elevated activity of serum TNFα was 
observed in cows with moderate to severe fatty liver (Ohtsuka et al., 2001). In light of these 
findings, we hypothesized that chronic low-grade inflammation may be a mechanism underlying 
bovine fatty liver. In fact, we found that low-level administration of the recombinant bovine 
TNFα (rbTNFα) for 7 d promoted liver inflammation and TG accumulation (Bradford et al., 
2009). However, late-lactation animals were used in that work, and it is unclear if this model is 
applicable to cows in the first week of lactation, when fatty liver naturally occurs. Beyond direct 
promotion of fatty liver, hepatic inflammation may lso affect glucose production. Bradford et al. 
(2009) reported that rbTNFα administration reduced liver gluconeogenic gene expr ssion in late-
lactation cows. If inflammatory cytokines impair glucose production in early-lactation animals, 
the resulting hypoglycemia would likely increase adipose TG mobilization and metabolic 
disorders.  
We hypothesized that metabolic stress in early-lactation cows is exacerbated by 
inflammatory challenge, thereby adversely affecting production and health. Therefore, the 
objective of this study was to determine whether exog nous rbTNFα administration promotes 
inflammation and TG accumulation, impairs gluconeogenesis, alters lipid metabolism, and 
affects milk production and health status in early-lactation dairy cows. A greater understanding 
of the pathological impact of inflammatory pathways in these animals may improve our ability to 





 Materials and Methods 
The Kansas State University Institutional Animal Care nd Use Committee approved all 
experimental procedures. 
 
 Design and Treatments  
A recombinant expression vector encoding the secretd form of bovine TNFα (Entrez 
Protein Accession AAB84086.1, region 77–233) was expr ssed in Escherichia coli and purified 
by a commercial laboratory (GenScript Corp., Piscataw y, NJ). Purity of the isolated rbTNFα 
was verified by SDS-PAGE, and endotoxin was removed using polymyxin B until contamination 
was less than < 1 EU/µg protein. Thirty-three Holstein cows (9 primiparous and 24 multiparous; 
body condition score: 3.26 ± 0.31, body weight 741 ± 83 kg; mean ± SD) were randomly 
assigned to 1 of 3 treatments at parturition. Treatm nts were balanced within parity, and dystocia 
did not differ by treatment (calving difficulty scores: 1.36, 1.18, and 1.18 ± 0.5 for Control, 1.5 
µg/kg and 3.0 µg/kg TNF, respectively; 1 to 5 scale, with 1 = no difficulty). Treatments (dose per 
d) were no rbTNFα (Control; 10% glycerol in saline), 1.5 µg rbTNFα/kg body weight in saline 
with 10% glycerol, and 3.0 µg rbTNFα/kg body weight in saline with 10% glycerol. These doses 
are slightly less and slightly more, respectively, than the 2.0 µg/kg dose that was previously 
shown to alter hepatic nutrient metabolism in lactating cows (Ohtsuka et al., 2001). Glycerol was 
included in the solution to improve solubility of the rbTNFα protein. Cows were injected 
subcutaneously once daily (1600 h) for the first 7 d of lactation. Cows were milked 3 times daily 




libitum intake of a diet formulated to meet National Research Council (NRC, 2001) nutrient 
requirements. Ingredient and nutrient composition of the diet are shown in Table 1. 
 
 Sample and Data Collection and Analysis 
 Feed Intake, Milk Production, Energy Balance, and Health Monitoring 
During the 7-d experimental period, intake of feed an  water and milk yield were 
recorded daily. Milk samples were collected from d 4 to 7 of treatment at each of the 3 milkings 
for analysis of milk components. Samples were analyzed for concentrations of fat, true protein, 
lactose (B-2000 Infrared Analyzer; Bentley Instruments Inc., Chaska, MN), urea nitrogen (MUN 
spectrophotometer, Bentley Instruments Inc.), and somatic cells (SCC 500, Bentley Instruments 
Inc., Heart of America DHIA, Manhattan, KS). Somatic cell linear score was calculated as 
described by Shook (1993): log2(somatic cell count/100) + 3. Energy balance was calcul ted for 
each cow using the following equation from NRC (2001): energy balance = net energy intake − 
(net energy of maintenance + net energy of lactation). Net energy intake = dry matter intake × 
net energy density of the diet (NRC, 2001); net energy of maintenance = 0.08 × body weight0.75; 
net energy of lactation = [(0.0929 × fat %) + (0.0547 × protein %) + (0.0395 × lactose %)] × 
milk yield. In all equations, energy is expressed in Mcal and mass in kg. 
Cows were monitored daily for health status. Ketosis was recorded when urine 
acetoacetate exceeded 80 mg/dL on any day or 40 mg/dL for 2 consecutive days (Ketostix; 
Bayer Corp. Diagnostics Division, Elkhart, IN). Fever was diagnosed when a cow had a rectal 
temperature greater than 39.4°C. Other disorders or diseases, including mastitis, metritis, and 





 Plasma Metabolites and Hormones  
Blood samples were collected from coccygeal vessels dai y (0800 h) in 2 tubes, one 
containing potassium EDTA and the other containing potassium oxalate with sodium fluoride as 
a glycolytic inhibitor (Vacutainer; Becton Dickinson, Franklin Lakes, NJ). Blood was 
centrifuged at 2,000 × g for 10 min immediately after sample collection, and plasma was frozen 
at -20°C until further analysis. Plasma samples colle ted daily during the 7-d treatment period 
were analyzed for NEFA (NEFA-HR; Wako Chemicals USA Inc., Richmond, VA), glucose (kit 
#439-90901; Wako Chemicals USA Inc.), BHBA (kit #H7587-58; Pointe Scientific Inc., Canton, 
MI), and TG (#10010303; Cayman Chemical, Ann Arbor, MI). Plasma samples collected on d 0, 
3, 5, and 7 of treatment were analyzed for TNFα (an ELISA method described by Farney et al., 
2011), insulin (ELISA kit #10-1201-01; Mercodia AB, Uppsala, Sweden), and haptoglobin 
(ELISA kit #2410-7; Life Diagnostics, West Chester, PA). Plasma samples collected on d 7 of 
treatment were analyzed for 3-methylhistidine. Samples were prepared by mixing 500 µL of 
plasma with 500 µL of Seraprep (Pickering Labs, Mountain View, CA) and frozen overnight. 
The deproteinized plasma was then thawed, vortexed, and centrifuged at 17,000 × g for 10 min. 
The resulting supernatant was analyzed for 3-methylhistidine using Li+ cation exchange 
chromatography and detection by fluorimetry following post column derivitization with o-
phthalaldehyde. The HPLC column and all reagents and eluents were purchased from Pickering 
Labs (Mountain View, CA). Column flow rate was 0.375 mL/min and column temperature was 
maintained at 36oC. Injection volumn was 10 µL. Eluent 1 (Li357) was run for 5 min then eluent 
2 (Li750) for 15 min and eluent 3 (RG003) for 5 min. The column was then re-equilibrated back 
to eluent 1 for 20 min. Post column derivitization was performed using a post column mixing T 




phthalaldehyde, 2.0 g Thiofluor, and 3 mL 30% Brij 35. The fluorimeter excitation was set to 
330 nm and emission to 465 nm. 
 
 Plasma Eicosanoids 
Plasma samples collected on d 0, 1, 3, and 5 of treatm nt were analyzed for eicosanoids 
as previously described (Farney et al., 2011). Plasma amples (500 µL) were mixed with 1 mL 
ice cold methanol, 6 µL antioxidant/reducing agent containing EDTA, butylhydroxytoluene, 
triphenylphosphine, and indomethacin (4 µL/mL), 200 µL of a mixture of internal standards, and 
1 µL of formic acid. Sample mixtures were centrifuged at 4°C for 10 min at 3,000 × g, and the 
supernatant was used for solid-phase extraction using Strata-X SPE columns (Phenomenex Inc., 
Torrance, CA). Eicosanoids were isolated using 2 distinct ultra-high–pressure liquid 
chromatography (UPLC) and mass spectrometry (UPLC-MS) methods. Both methods used 
reverse-phase liquid chromatography on an Acquity UPLC BEH C18 1.7-µm column 
(2.1 × 100 mm; Waters Corp., Milford, MA) at a flow rate of 0.6 mL/min at 35°C and a single-
quadrupole H-class Acquity SQD mass spectrometer in lectrospray negative ionization mode 
(Waters Corp.). The electrospray voltage was −3 kV, and the turbo ion spray source temperature 
was 450°C. Nitrogen was used as the drying agent. For each method, a 10-µL sample was 
injected 3 consecutive times using a 10-µL injection loop. An isocratic mobile phase consisting 
of acetonitrile/water/formic acid (45/55/0.01; vol/vol/vol) with an analysis time of 15 min was 
used to measure leukotriene B4 (LTB4), thromboxane B2 (TXB2), prostaglandin E2 (PGE2), 
prostaglandin F2 (PGF2), lipoxin A4, resolvin D1, and resolvin D2. The second method used an 
isocratic mobile phase of acetonitrile/methanol/water/formic acid (47.4/15.8/26.8/0.01; 




(HODE), 13-HODE, 9-oxo-octadecadienoic acid (oxoODE), 13-oxoODE, 5-
hydroxyeicosatetraenoic acid (HETE), 15-HETE, 7-maresin 1, leukotriene D4 (LTD4), and 
protectin.  
Quantitation of eicosanoid concentrations was performed with Waters Empower 2 
software (Waters Corp.). A linear calibration curve with 5 points (R2 > 0.99) was generated for 
each eicosanoid with standards and internal standards purchased from Cayman Chemical Co. 
(Ann Arbor, MI). The curves ranged from 0.0024 to 2.38 ng/µL. Empower 2 identified the 
sample peak by matching its retention time with the standard. A response was calculated for each 
matched peak by dividing the sample peak’s response by its internal standard’s response. This 
response was multiplied by the concentration of the internal standard for each analyte. The 
concentration of each analyte was calculated using the response peak and injection volume. 
 
 Glucose Turnover Rate 
After daily blood sampling on d 5 of treatment, jugular vein catheters were placed and at 
least 18 h of recovery were allowed prior to sample collection through the catheters. On 
treatment d 7, cows were given a glucose bolus containi g U-13C-glucose (99 atom %, Sigma-
Aldrich Co., St. Louis, MO) through jugular catheters (Schulze et al., 1991). Jugular blood 
samples were collected 10 min prior to infusion andt 10, 20, 30, 40, 50, 60, 90, and 120 min 
post-infusion. Each cow received approximately 1 g of U-13C-glucose in 50 mL of sterile saline; 
syringes were weighed immediately before and after infusion to determine the exact amount 
administered. Catheters were flushed with a sterile so ution of 3.5% sodium citrate after the 
labeled glucose bolus (20 mL) and after each blood sample collection (5 mL). Plasma glucose 




Plasma samples collected for the glucose turnover assay were analyzed for U-13C-glucose 
enrichment (Metabolic Solutions, Inc., Nashua, NH). Glucose was extracted and converted to 
aldonitrile pentaacetate derivative (Tserng and Kalhan, 1983), and negative chemical ionization 
GC/MS (Hewlett-Packard 5890; Agilent Technologies, Santa Clara, CA) was used to analyze 
derivatized samples. The isotopic composition of the glucose was determined by monitoring 
unlabeled (M+0: m/z = 328) versus U-13C-labeled (M+6: m/z = 334) glucose derivatives. This 
approach, as opposed to oxidation of glucose and measur ment of CO2 enrichment, ensures that 
results are not biased by carbon recycling via the Cori cycle. Turnover rate of plasma glucose 
was calculated from the disappearance curve for U-13C-glucose. Enrichment of plasma glucose 
for each animal was fitted to an exponential decay curve according to the following equation: Et 
= E0 × e
-kt, where t = time relative to infusion (min), Et = enrichment of plasma glucose (U-
13C-
glucose: unlabeled glucose ratio) at time t, E0 = enrichment at time t = 0, and k = rate constant 
(min-1). After using the best-fit equations to determine k and E0, the total glucose pool was 
calculated by the following equation: G = M ÷ E0, where G = total glucose pool (g) and M = 
mass of tracer infused (g). Plasma glucose turnover rat  (GTR, g/min) was calculated according 
to the equation GTR = G × k. Samples collected 10 min prior to infusion of U-13C-glucose were 
also analyzed to verify the lack of natural occurrence of the M+6 isotopomer. 
 
 Liver TG 
At the end of treatment d 7, liver samples were colle ted by percutaneous biopsy as 
described by Morey et al. (2011). For analysis of TG content, approximately 20 mg of liver was 
placed into 500 µL of chilled phosphate buffered saline (pH 7.4) andhomogenized. The 




then removed for free glycerol and total protein analyses. Triglyceride content was measured 
using a method adapted from Starke et al. (2010). The remaining liver homogenate was 
incubated with 100 µL of lipase (porcine pancreatic lipase; MP Biomedicals, Solon, OH) for 16 h 
at 37°C, and glycerol content was then determined by an enzymatic glycerol phosphate oxidase 
method (#F6428, Sigma-Aldrich Co.). Triglyceride content was calculated based on the 
difference between glycerol concentrations before and after lipase digestion. Total protein 
content of the original homogenate was analyzed by a Coomassie blue (Bradford, 1976) 
colorimetric method (kit #23236; Thermo Scientific Pierce, Rockford, IL). To avoid potential 
bias introduced by differences in moisture content of liver samples, liver TG concentration was 
normalized by protein concentration, which is unaltered in fatty liver (Fronk et al., 1980). 
 
 Transcript Abundance 
Total RNA was extracted from liver tissue using a commercial kit (RNeasy Lipid Tissue 
Mini Kit; Qiagen Inc., Valencia, CA) according to the manufacturer's instructions. Two 
micrograms of total RNA was used as the template for the reverse transcriptase reaction using 
random primers (High-Capacity cDNA RT Kit; Applied Biosystems, Foster City, CA). 
Quantitative real-time PCR was performed in duplicate on 96-well plates with 5% of the cDNA 
product in the presence of 200 nM gene-specific forward and reverse primers with real-time 
SYBR green fluorescent detection using SYBR Green Pr mix reagent (7500 Fast Real-Time 
PCR System, Applied Biosystems). Primers were design d (www.ncbi.nlm.nih.gov/tools/primer-
blast/) using GenBank sequences (Table 2). Data were recorded and analyzed with Sequence 
Detector software (Applied Biosystems). All sample values were normalized against ribosomal 




quantified by using the 2−∆Ct method. Treatment did not influence the Ct value for RPS9 (P = 
0.56), suggesting that it served as a valid control gene.  
 
 Western Blot  
Relative protein abundance of IκBα, c-Jun, phosphorylated c-Jun, and TNFα in liver 
samples was determined by Western blot. Liver samples (~20 mg) were homogenized at 4°C in 
RIPA lysis buffer containing a broad-spectrum protease inhibitor cocktail (Protease Inhibitor 
Cocktail I; EMD Millipore, Billerica, MA) and a phosphatase inhibitor (PhosphoStop; Santa 
Cruz Biotechnology, Santa Cruz, CA). The homogenate was centrifuged at 15,000 × g for 10 
min at 4°C, and total protein concentration of the supernatant was measured (Bradford, 1976). 
Forty micrograms of total protein from liver tissue was heated at 90°C for 5 min, vortexed, and 
loaded onto a 4 to 12% Tris-HCl gel for electrophoresis. Samples were separated by SDS-PAGE 
and dry-transferred onto nitrocellulose membranes (iBlot; Invitrogen, Carlsbad, CA). 
Membranes were blocked for 2 h in blocking buffer (5% dry milk in Tris-HCl buffer, pH 7.5, 
with 0.05% Tween 20). After incubation with blocking buffer, the membranes were washed 3 
times for 5 min each with washing buffer (phosphate-buffered saline, pH 7.5, containing 0.05% 
Tween 20). Membranes were then incubated with primary antibodies (diluted 1:250) from Santa 
Cruz Biotechnology against IκBα (catalog #sc-847), c-Jun (#sc-44), and phosphorylated c-Jun 
(#sc-822) overnight at 4°C. After washing, secondary antibody diluted 1:10,000 was incubated 
for 1 h at room temperature. Antibody incubation and detection for TNFα was carried out as 
previously described (Bradford et al., 2009). Immunodetection was performed by 
chemiluminescence (West-Dura; Thermo Scientific, Waltham, MA), and bands were quantified 





 Calculations and Statistical Analyses  
One cow that received 3 µg/kg rbTNFα developed a severe fever on d 6 of treatment, and 
the d 7 treatment was not given. Consequently, the liver biopsy and glucose turnover test were 
not conducted for this cow, but all other data were r tained through d 6. Plasma glucose data 
indicated that 2 cows did not meet steady-state conditi s during the glucose turnover test; these 
cows were not used for turnover rate analysis. In total, data from 33, 32, and 30 cows were used 
for production responses and plasma analyses, liver tissue analyses, and glucose turnover 
analysis, respectively. Data were analyzed using the MIXED Procedure of SAS (version 9.2; 
SAS Institute Inc., Cary, NC) to assess the fixed effects of treatment, parity, time, and 2- and 3-
way interactions; cow was included as a random effect. Data were log-transformed for analysis 
when necessary (including plasma concentrations of TNFα and 3-methylhistidine, and hepatic 
transcript abundance of AGPAT1, PCK1, and CPT1a) to achieve a normal distribution of 
residuals, and data presented are back-transformed in these cases. Repeated measures over time 
were modeled with either autoregressive or heterogeneous autoregressive covariance structures, 
depending on which analysis had the lowest Bayesian Information Criterion value. Denominator 
degrees of freedom were estimated using the Kenward-Rogers method. Values were deemed 
outliers and omitted from analysis when Studentized residuals were > 3.5 or < -3.5. Interactions 
were investigated when P < 0.10 using the slice option, and slices were declar d significant at P 
< 0.05. Contrasts were used to evaluate Control vs. rbTNFα treatments and 1.5 µg/kg vs. 3.0 
µg/kg rbTNFα doses. Health disorders were analyzed using JMP (version 8.0; SAS Institute Inc., 
Cary, NC). A nominal logistic analysis was first run for each health disorder to assess the fixed 




interaction P < 0.10, Fisher’s exact test was used to assess rbTNFα and dose contrasts within 
each parity group. For all other disorders, Fisher’s xact test was used to test these contrasts 
across all animals. Significance was declared at P ≤ 0.05 and tendencies at 0.05 < P  0.10. 
 
 Results 
 Inflammatory Signals 
Compared with Control, plasma TNFα concentrations tended to be increased (P = 0.09) 
by rbTNFα treatments, but 1.5 µg/kg did not differ (P = 0.19) from 3 µg/kg rbTNF (Figure 1A). 
Plasma haptoglobin concentrations were greater (P < 0.01, Figure 1B) in rbTNFα treatments than 
Control, but did not differ between 1.5 and 3 µg/kg rbTNF (P = 0.68). Across the 3 groups, 
haptoglobin levels were comparable (P = 0.94) at parturition, but increased during the first week 
of lactation in response to rbTNFα. On d 5 and 7 of treatment, rbTNFα treatments increased 
haptoglobin concentration by ~2.5- and ~3.5-fold, respectively, compared with Control. 
Plasma eicosanoid results are shown in Table 3. Most eicosanoids were unaffected (P > 
0.10) by treatments; out of the 16 measured eicosanoids, only 9-oxoODE was decreased (P = 
0.01) by rbTNFα administration. The pro-inflammatory class as a comp site was unaffected by 
treatments; however, the anti-inflammatory class tended (P = 0.08) to be decreased by the 3 
µg/kg compared with 1.5 µg/kg rbTNFα dose (Figure 2), though rbTNFα treatment did not differ 
from Control (P = 0.22).  
Plasma eicosanoids with significant (P < 0.05) day effects are presented in Table 4. 
Plasma concentrations of TXB2, 15-HETE, and 9-HODE were elevated around parturition and 




gradually after parturition. The pro-inflammatory class decreased (P = 0.02) during the first 
week of lactation, whereas the anti-inflammatory class (P < 0.01) increased after parturition. 
As shown in Figure 3A, hepatic transcript abundance of TNFα was increased (P = 0.02) 
by 3 µg/kg compared with 1.5 µg/kg rbTNFα, but overall, rbTNFα treatments did not differ 
from Control (P = 0.73). There were no treatment effects (P > 0.10) for protein abundance of 
TNFα, c-Jun, or relative c-Jun phosphorylation (Figure 3B). There was a tendency for a 
treatment × parity interaction (P = 0.07) for IκBα, reflecting increased (P = 0.04) IκBα 
abundance by rbTNFα treatment in primiparous cows (data not shown). Compared with 
primiparous cows, IκBα was decreased (P = 0.02), TNFα was increased (P = 0.04), and relative 
c-Jun phosphorylation was decreased (P = 0.04) in multiparous cows (Figure 3C). 
 
 Energetics 
Dry matter and water intake were decreased (P < 0.05) by rbTNFα treatments, but no 
dose effect (P > 0.10) was observed (Table 5). Cows were in negative energy balance during the 
experimental period, and the energy balance values were not affected (P > 0.10) by treatments. 
Milk yield was decreased (P = 0.03) by rbTNFα treatments, with no dose effect (P = 0.76). 
Similar to milk yield, milk energy output was decreas d (P < 0.01) by rbTNFα administration. 
Milk fat percentage was decreased (P = 0.02) by 3.0 µg/kg rbTNFα compared with the 1.5 µg/kg 
dose, but overall, rbTNFα treatments did not differ from Control (P = 0.55). Nevertheless, milk 
fat yield was decreased (P = 0.01) in cows treated with rbTNFα, and there was a tendency for 
decreased (P = 0.07) milk fat yield for the 3.0 µg/kg rbTNF dose compared with 1.5 µg/kg. Milk 




decreased (P < 0.01) by rbTNFα administration. Milk urea nitrogen concentration and somatic 
cell linear score were not affected (P > 0.10) by treatments. 
 
 Metabolism 
Plasma concentrations of glucose, insulin, BHBA, NEFA, TG, and 3-methylhistidine, and 
liver TG were not affected (P > 0.10, Table 6) by rbTNFα treatment. Glucose turnover rate 
(Table 6) was unaffected (P = 0.18) by rbTNFα treatments. When expressed relative to dry 
matter intake (daily glucose turnover rate/day 7 dry matter intake), 3 µg/kg rbTNFα was greater 
(P < 0.01) than other treatments. 
As shown in Figure 4, the mRNA abundance of mitochondrial carnitine 
palmitoyltransferase 1a (CPT1a) was increased (P < 0.01) by rbTNFα treatments, with 3 µg/kg 
greater (P = 0.04) than 1.5 µg/kg rbTNF. No treatment effects (P > 0.10) were detected for 
apolipoprotein B (ApoB), 1-acylglycerol-3-phosphate O-acyltransferase 1 (AGPAT1), 
phosphoenolpyruvate carboxykinase 1 (PCK1), or pyruvate carboxylase (PC).  
 
 Health Disorders  
Incidence of health disorders is shown in Table 7. There was a tendency for increased (P 
= 0.08) risk of experiencing 1 or more health disorders for 3 µg/kg compared with 1.5 µg/kg 
rbTNFα, although the overall rbTNFα effect was not significant (P = 0.25). Ketosis incidence 
reported in Table 7 was based on detection of urine ketones; of the cows identified by this 




concentrations that exceeded 3 mM on at least one day, i entifying them as clinical cases, 
whereas the 2 others exceeded the 1.4 mM threshold for subclinical ketosis (Oetzel, 2007). 
 
 Discussion 
Our previous research demonstrated that administration of 2 µg/kg body weight rbTNFα 
daily for 7 d was adequate to mimic a chronic low-grade inflammatory state without causing 
acute systemic inflammation in late-lactation cows (Bradford et al., 2009). Therefore, in the 
present study, we administered 1.5 and 3 µg/kg rbTNFα in an attempt to characterize a similar 
low-grade inflammation in early-lactation cows, whic  experience dramatic energy demands of 
milk production and tremendous metabolic stress compared with late-lactation animals. 
Although blood samples were collected 16 h after th previous injection, we still observed a 
tendency for elevated plasma TNFα concentrations in treated cows, indicating a sustained 
chronic inflammation status in cows receiving rbTNFα. Moreover, 3 µg/kg rbTNFα 
administration increased hepatic transcript abundance of TNFα, further supporting that treatment 
enhanced pro-inflammatory responses.   
We also evaluated plasma concentrations of haptoglobin and eicosanoids, and the protein 
abundance of key inflammatory mediators in the liver. Haptoglobin is an acute phase protein 
primarily released by the liver in inflammation (Hachenberg et al., 2007). Our finding that 
rbTNFα increased haptoglobin agrees with a previous study that daily administration of 2.5 
µg/kg rbTNFα for 7 d dramatically elevated plasma haptoglobin in lactating cows (Kushibiki et 
al., 2003). Interestingly, haptoglobin elevation has been associated with bovine fatty liver (Bobe 
et al., 2004), suggesting that liver TG accumulation may be associated with inflammation. 




accumulation per se, causes liver damage through promoting lipotoxicity, oxidative stress, and 
inflammatory reactions (Neuschwander-Tetri, 2010). In the present study, neither NEFA nor 
liver TG were affected by treatments, suggesting that rbTNFα increased haptoglobin independent 
of altered lipid mobilization.  
Eicosanoids are a family of signaling molecules produced by oxidation of 20-carbon 
essential fatty acids. They exert complex control over inflammation, and can either enhance 
(such as certain types of prostaglandins, thromboxanes, and leukotrienes) or resolve (such as 
resolvins, protectins, and maresins) inflammatory responses depending on their types and the 
timing of production (Sordillo et al., 2009). The increased lipolysis and elevated plasma NEFA 
in early lactation may increase the supply of fatty cid substrates for eicosanoid production, 
thereby affecting the duration and magnitude of inflammation. In the present study, 6 out of the 
16 measured plasma eicosanoids were significantly altered over time, but few treatment effects 
were detected for eicosanoids. One interesting finding was that the highest dose of rbTNFα 
tended to suppress the anti-inflammatory eicosanoid class, primarily reflecting decreased 
concentrations of 7-maresin 1, protectin, and 9-oxoODE. We are unaware of evidence in the 
literature of cytokines inhibiting release of anti-i flammatory eicosanoids, but such an effect is 
consistent with the pro-inflammatory effects of TNFα (Hotamisligil et al., 1995). We cannot rule 
out the possibility that decreases in anti-inflammatory eicosanoids may have been driven by an 
unknown mediator rather than a direct effect of TNFα. Still, it is intriguing that rbTNFα 
administration apparently did more to suppress the production of resolving lipid mediators than 
to enhance the production of inflammatory lipids, and this result should inform choices about 




We found that concentrations of pro-inflammatory eicosanoids, including certain types of 
prostaglandins and thromboxanes, were elevated around parturition and decreased during the 
first week of lactation, whereas pro-resolving metabolites, such as resolvin D2 and 7-maresin 1, 
increased after parturition. Consistent with the results of the above-mentioned eicosanoids, the 
composite pro-inflammatory class was elevated at parturition and decreased thereafter, whereas 
the anti-inflammatory class changed in the opposite dir ction. Although the inflammatory state 
of postpartum dairy cows has been well documented (Bionaz et al., 2007), these are the first data 
to document an increase in anti-inflammatory eicosan ids during the resolution of inflammation 
as lactation proceeds. The causative role of eicosanoids in this resolution phase should be a 
fruitful area for further investigation. 
Nuclear factor-κB (NF-κB) is a key transcription factor that plays crucial roles in 
inflammation (Karin and Ben-Neriah, 2000). In nonstimulated cells, NF-κB is bound to 
inhibitory IκB proteins and sequestered in the cytoplasm. Activation of NF-κB primarily occurs 
via the phosphorylation, ubiquitination, and degradation of IκB proteins; subsequently, the 
liberated NF-κB is translocated to the nucleus to drive expression of inflammatory genes (Häcker 
and Karin, 2006). One of the major IκB proteins in inhibiting NF-κB activation is IκBα, the 
abundance of which can be used to estimate anti-inflammatory status. In this study, hepatic IκBα 
abundance was significantly increased by rbTNFα in primiparous cows. This observation is 
unexpected, because TNFα is a potent activator of IκBα degradation (Karin and Ben-Neriah, 
2000), and suggests the involvement of compensatory nti-inflammatory adaptations in response 
to rbTNFα.  
 We also investigated the inflammatory mediator c-Jun, which is a key component 




Jun is increased by phosphorylation of serine residues in response to various stimuli, including 
inflammation (Lee et al., 2001). As for the NF-κB pathway, we found no evidence of hepatic c-
Jun activation in response to rbTNFα. Collectively, rbTNFα treatment did not significantly alter 
the hepatic protein abundance of inflammatory mediators, but nevertheless greatly increased the 
plasma concentration of haptoglobin, an acute phase prot in induced primarily by inflammatory 
signals in the liver (Nakagawa-Tosa et al., 1995). It is possible that haptoglobin was primarily 
induced by transcription factors other than NF-κB or activator protein-1. 
In this study, feed intake and milk production were decreased by rbTNFα treatments by 
18 and 15%, respectively. TNFα is a key mediator causing anorexigenic responses in var ous 
diseases, and many of the effects of TNFα are dependent on its actions in the hypothalamus 
(Romanatto et al., 2007). Interestingly, our previous research in late-lactation cows showed that 
2 µg/kg rbTNFα treatment daily for 7 d also decreased feed intake by 18%, but did not 
significantly alter milk production (Bradford et al., 2009). Kushibiki et al. (2003) reported that 
daily administration of 2.5 µg/kg rbTNFα for 7 d dramatically decreased feed intake (by ~34%) 
and milk yield (by ~15%). As expected, cows were in negative energy balance during the 
immediate postpartum period, indicating that their energy expenditure, driven largely by 
lactation requirements, greatly exceeded their energy intake. However, energy balance values 
were not affected by rbTNFα administration because the magnitude of decreased milk 
production was comparable to that of decreased feed intake. 
Administration of rbTNFα did not alter plasma markers of lipid metabolism or promote 
fatty liver. As a lipolytic mediator in adipose tissue (Zhang et al., 2002), previous studies found 
that rbTNFα administration at 2.5 µg/kg significantly increased plasma NEFA concentrations in 




previously reported that 7-d rbTNFα administration at 2 µg/kg daily increased liver TG by ~2-
fold (Bradford et al., 2009). It is possible that because plasma NEFA and BHBA concentrations, 
as well as liver TG content, were already dramatically elevated in response to negative energy 
balance in the periparturient period, the doses of rbTNFα used in this study were insufficient to 
promote further alterations in lipid metabolism. Onthe transcriptional level, our previous work 
(Bradford et al., 2009) in late-lactation cows showed that 2 µg/kg rbTNFα administration daily 
for 7 d increased the transcript abundance of AGPAT1 (which catalyzes the esterification of a 
fatty acyl-CoA to the sn-2 position of the glycerol backbone in TG synthesis), tended to decrease 
CPT1a (which catalyzes transport of fatty acids into mitochondria for oxidation), and did not 
affect ApoB (which is a key component of very low-density lipopr tein that mediates hepatic TG 
exportation). Here, we did not find treatment effects for AGPAT1 or ApoB, and found that 
rbTNFα increased CPT1a abundance dose-dependently. Collectively, rbTNFα did not promote 
the pathways favoring hepatic lipid accumulation in early-lactation cows. 
Lactating cows rely heavily on hepatic gluconeogenesis to meet glucose requirements 
because the majority of dietary carbohydrates are fermented in the rumen. Under steady-state 
conditions, the rate of glucose appearance equals the ra e of its disappearance, and the calculated 
glucose turnover rate approximately equals gluconeogenesis in ruminants, because net portal 
appearance of glucose is negligible (Young, 1977). In this study, there were no treatment effects 
on plasma glucose or insulin, abundance of key gluconeogenic transcipts, or plasma glucose 
turnover rate, indicating that low-grade inflammation did not affect hepatic gluconeogensis in 
early-lactation cows. Previous data regarding TNFα effects on gluconeogensis have been 
inconsistent. Short-term recombinant human TNFα administration at 10 µg/kg, but not 3.5 µg/kg, 




rate in dogs; coupled with decreased fatty acid flux, the authors concluded that TNFα given in a 
high dose causes a shift toward carbohydrate as an energy substrate (Sakurai et al., 1993). In a 
subsequent study, Sakurai et al. (1996) infused 2.5 µg/kg TNFα in dogs for 2 h and did not 
observe a change in glucose production.  
The primary substrate for gluconeogenesis in ruminants is propionate, a short-chain fatty 
acid derived from ruminal fermentation; as a result, liver glucose production in cows is often a 
function of energy intake (Reynolds et al., 2003). To assess whether gluconeogenesis was 
affected by substrate supply, we expressed glucose production relative to feed intake. 
Interestingly, this analysis revealed that the 3 µg/kg rbTNFα treatment increased the apparent 
efficiency of gluconeogenesis from dietary substrates, primarily because of the low feed intake 
for that treatment. Given that propionate is used for glucose production at >90% efficiency in 
ruminants (Steinhour and Bauman, 1988), increased metabolic efficiency was not likely the 
reason for this response. When requirements are greater than nutrient intake, such as in early 
lactation, the contributions of lactate, glycerol, and amino acids from body tissues to 
gluconeogenesis increase markedly (Bell, 1995). Glycerol is released primarily from adipose TG 
mobilization, which was likely unaffected by treatments (based on unaltered plasma NEFA). In 
an attempt to evaluate whether 3 µg/kg rbTNFα-treated cows had greater amino acid supply from 
protein mobilization, we measured concentrations of plasma 3-methylhistidine, a marker of 
muscle protein breakdown that has been shown to increase rapidly during the periparturient 
period and peak at 1 week after parturition (Blum et al., 1985). Treatment effects on plasma 3-
methylhistidine were not significant; however, the 3 µg/kg rbTNFα treatment mean was 




enhanced muscle proteolysis and decreased amino acid use for milk protein synthesis resulted in 
greater supply of amino acids for gluconeogenic substrate in the 3 µg/kg rbTNFα treatment. 
Despite the lack of dramatic alterations in metabolism, the higher dose of rbTNFα tended 
to impair the health of postpartum cows. Health disorders affect considerable numbers of 
periparturient dairy cows, compromising animal welfare, milk production, and fertility. Ketosis 
is considered the most important metabolic disease in the U.S. dairy industry (Oetzel, 2007), and 
ketotic cows are also at increased risk for other disor ers, such as displaced abomasum and 
metritis (Duffield et al., 2009). Ketosis may increas  the risk of infectious disorders through 
negative effects of ketone bodies on immune cell function (Grinberg et al., 2008). In this study, 
rbTNFα increased the incidence of ketosis by 3-fold in the first week of lactation, accounting for 
much of the increase in total disease incidence. Thre are numerous mechanisms by which 
rbTNFα may have promoted subclinical ketosis, but poor feed intake in early lactation is a key 
risk factor for ketosis (Grummer, 1995), and it is likely that the suppression of intake by rbTNFα 
played a role in this study. Decreased feed intake did not decrease energy balance or increase 
lipolysis in this study, but low intake affects more than just energy status; decreased protein, 
mineral, vitamin, or lipid intake may have adversely affected health. 
 
 Conclusions  
In conclusion, rbTNFα treatment during the first 7 d of lactation decreased feed intake, 
reduced milk production, and tended to impair health status, but did not significantly alter 
glucose or lipid metabolism. These data indicate that in response to low-grade inflammation, 
early-lactation cows compensate for the reduced intake by suppressing milk production rather 




physiological response to inflammatory mediators can be considered a biological tradeoff 
between lactational performance and survival (Ballou, 2012). However, because effects on feed 
intake and milk yield occurred simultaneously, it is unclear whether one or the other was a 
secondary response. Further studies are needed to investigate if inflammation directly alters 
mammary or neurological function. Nevertheless, this study indicates that preventing excessive 
inflammation in early lactation has the potential to improve productivity and health of dairy cows. 
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Table 2-1 Ingredient and nutrient composition of the diet. 
 
Item Value 
Ingredient, % of dry matter  
 Corn silage 22.2 
 WCGF1 30.3 
 Alfalfa hay 20.4 
 Cottonseed 4.9 
 Corn grain 9.2 
 Sorghum grain 4.0 
 Micronutrient premix2 9.0 
Nutrient, % of dry matter  
 Dry matter (% as-fed) 58.6 
 Crude protein 17.3 
 Acid detergent fiber 17.8 
 Neutral detergent fiber 31.8 
 Ether extract 5.0 
 Ash 9.1 
 Net energy for lactation3 (Mcal/kg dry matter) 1.72 
 
1 Wet corn gluten feed (Sweet Bran; Cargill Inc., Blair, NE). 
2 Premix consisted of 54.9% expeller soybean meal, 14.3% limestone, 10.2% sodium bicarbonate, 
10.0% calcium salts of long-chain fatty acids (Megalac-R; Arm & Hammer Animal Nutrition, 




magnesium oxide, 1.6% potassium carbonate, 1.6% salt, 1.6% Vitamin E premix (44 IU/g), 0.6% 
4-Plex (Zinpro Corp., Eden Prairie, MN; consists of zinc 2.58%, manganese 1.48%, copper 
0.90%, cobalt 0.18%, methionine 8.21%, and lysine 3.80%), 0.3% selenium premix (0.06% Se), 
0.1% Vitamin A premix (30 kIU/g), 0.1% Vitamin D premix (30 kIU/g), 0.1% Rumensin 90 
(Elanco Animal Health, Greenfield, IN), and 0.1% Zinpro 100 (Zinpro Corp., Eden Prairie, MN; 
consists of 10% zinc and 30% methionine). 





Table 2-2 Primers used for real-time PCR gene expression analysis. 
 
Gene1 Sequences of primers (5’ to 3’) Accession number2 Amplicon 
region 
Median Ct Efficiency3 
AGPAT1 Forward, GGAGTCATCTTCATTGACCGGA NM_177518.1 737-847 29.3 99% 
 Reverse, GCCCTCAGGAAAAACCCA     
ApoB Forward, TCCTTGATTCCACATGCAGCT XM_003582812.1  11567-11666 20.6 94% 
 Reverse, GGTGTGCAAAGGATGCGTTAG     
CPT1a Forward, CTTCCCATTCCGCACTTTC  XM_002699420.2 1950-2033 22.6 93% 
 Reverse, CCATGTCCTTGTAATGAGCCA     
PC Forward, CTTCAAGGACTTCACTGCCACC NM_177946.4 3160-3276 21.4 98% 
 Reverse, GCCAAGGCTTTGATGTGCA     
PCK1 Forward, CGAGAGCAAAGAGATACGGTGC NM_174737.2 427-542 18.5 98% 
 Reverse, TGACATACATGGTGCGACCCT     
RPS9 Forward, GAACAAACGTGAGGTCTGGAGG NM_001101152.2 170-261 19.2 92% 
 Reverse, TTACCTTCGAACAGACGCCG     




 Reverse, CTTCCAGCTTCACACCGTTG     
 
1 AGPAT1: 1-acylglycerol-3-phosphate O-acyltransferase 1; ApoB: apolipoprotein B; CPT1a: mitochondrial carnitine 
palmitoyltransferase 1A; PC: pyruvate carboxylase; PCK1: phosphoenolpyruvate carboxykinase 1; RPS9: ribosomal protein S 9; 
TNFα: tumor necrosis factor α. 
2 From NCBI Entrez Nucleotide Database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide). 
3 The coefficients of determination (R2) for all genes were greater than 0.98. 
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Table 2-3 Concentrations of plasma eicosanoids in early-lactation dairy cows during the 
experimental period. Eicosanoids were measured on day 0, 1, 3, and 5 of treatment. Values are 
least squares means ± SEM, n = 10-11. 
 
 Treatments2  P-value3 
Eicosanoids1, ng/mL Control 1.5 µg/kg 3.0 µg/kg SEM C vs. T4 Dose5  
PGE2 1.07 1.26 1.21 0.14 0.16 0.88  
PGF2 1.55 1.61 1.56 0.075 0.36 0.61  
LTB4
* 0.43 0.43 0.28 0.101 0.87 0.49  
LTD4 335 305 275 120 0.68 0.74  
TXB2 33.2 25.5 36.9 6.6 0.86 0.31  
9-HODE 30.4 31.7 27.4 3.6 0.89 0.64  
13-HODE 28.5 28.7 26.7 3.5 0.60 0.48  
5-HETE 94.9 96.1 65.3 18.2 0.26 0.25  
15-HETE 4.49 4.50 4.75 0.69 0.64 0.73  
Pro-inflammatory class6  482 426 384 95 0.40 0.63  
Resolvin D1 0.172 0.294 0.241 0.053 0.14 0.59  
Resolvin D2 19.3 16.6 8.6 4.7 0.22 0.26  
Lipoxin A4 1.84 1.38 1.29 0.33 0.31 0.90  
7-maresin 1 472 430 302 69 0.22 < 0.10  
Protectin 89.9 83.6 49.2 18.7 0.30 0.06  
9-oxoODE 54.1 46.0 46.0 3.2 0.01 0.86  
13-oxoODE 26.4 27.1 22.5 2.8 0.34 0.43  
 68
Anti-inflammatory class7 689 636 469 96 0.22 0.08 
 
1 LT: leukotriene; PG: prostaglandin; TX: thromboxane; HODE: hydroxyoctadecadienoic acid; 
HETE: hydroxyeicosatetraenoic acid; oxoODE: octadecienoic acid. 
2 Treatments: cows were given 0, 1.5, or 3.0 µg/kg body weight rbTNFα injections daily for the 
first 7 days of lactation, respectively. 
3 No treatment by day interactions were significant except as noted. 
4 Contrast between Control and rbTNFα treatments. 
5 Contrast between 1.5 and 3.0 µg/kg rbTNFα treatments. 
6 Pro-inflammatory class is the sum all of PGE2, PGF2, LTB4, LTD4, TXB2, 9-HODE, 13-
HODE, 5-HETE, and 15-HETE concentrations (Sordillo et al., 2009). 
7 Anti-inflammatory class is the sum of resolvin D1 and D2, protectin, lipoxin A4, 7-maresin 1, 
9-oxoODE, and 13-oxoODE concentrations (Sordillo et al., 2009). 
*A significant treatment × time interaction was detected (P < 0.04), but treatment contrasts 
were not significant on any individual day. 
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Table 2-4 Concentrations (across treatments) of plasma eicosanoids in early-lactation dairy 
cows with significant (P < 0.05) day effects during the experimental period. Values are least 
squares means ± SEM, n = 31-33. 
 
 Day2   
Eicosanoids1, ng/mL 0 1 3 5 SEM P-value 
PGF2 1.67 1.44 1.41 1.78 0.11 0.02 
TXB2 52 16 26 35 10 < 0.001 
Resolvin D2 5.1 12.2 21.8 20.4 3.7 < 0.01 
9-HODE 34.4 29.0 25.8 30.1 3.67 0.04 
15-HETE 6.7 4.4 3.7 4.2 1.04 0.03 
7-maresin 1 248 358 481 568 59 < 0.01 
Pro-inflammatory class3  531 369 374 460 70 0.02 
Anti-inflammatory class4 418 538 689 781 85 < 0.01 
 
1 PG: prostaglandin; TX: thromboxane; HODE: hydroxyoctadecadienoic acid; HETE: 
hydroxyeicosatetraenoic acid.  
2 Day of lactation. Plasma eicosanoids with significant (P < 0.05) day effects are presented.  
3 Pro-inflammatory class is the sum of PGE2, PGF2, LTB4, LTD4, TXB2, 9-HODE, 13-HODE, 
5-HETE, and 15-HETE concentrations (Sordillo et al., 2009). 
4 Anti-inflammatory class is the sum of resolvin D1 and D2, protectin, lipoxin A4, 7-maresin 1, 
9-oxoODE, and 13-oxoODE concentrations (Sordillo et al., 2009). 
  
 70
Table 2-5 Production responses in early-lactation dairy cows during the experimental 
period. Values are least squares means ± SEM, n = 10-11. 
 
 Treatments1  P-value2 
Item Control 1.5 µg/kg 3.0 µg/kg SEM C vs. T3 Dose4  
Dry matter intake, kg/d 13.7 12.1 10.4 0.80 0.02 0.15  
Water intake, L/d 79.8 71. 9 66.5 3.9 0.04 0.34  
Milk yield, kg/d 33.7 29.1 28. 4 1.7 0.03 0.76  
Milk fat, % 5.41 6.00 5.18 0.24 0.55 0.02  
Milk fat, kg/d 2.08 1.87 1.59 0.11 0.01 0.07  
Milk protein, % 3.51 3.57 3.37 0.11 0.75 0.19  
Milk protein, kg/d 1.29 1.11 1.01 0.05 < 0.01 0.19  
Milk lactose*, % 4.52 4.52 4.45 0.05 0.65 0.33  
Milk lactose, kg/d 1.65 1.39 1.32 0.08 < 0.01   0.55  
Milk energy output, Mcal/d 36.8 32.1 28.7 1.6 < 0.01 0.13 
Energy balance, Mcal/d -23.6 -21.6 -22.0 1.6 0.36 0.89 
Milk urea nitrogen, mg/dL 11. 1 12.7 12.3 0.75 0.13 0.75 
Somatic cell linear score 3.27 2.49 3.13 0.51 0.50 0.39 
 
1 Treatments: cows were given 0, 1.5, or 3.0 µg/kg body weight rbTNFα injections daily for the 
first 7 days of lactation, respectively. 
2 No treatment by day interactions were significant except as noted. 
3 Contrast between Control and rbTNFα treatments. 
4 Contrast between 1.5 and 3.0 µg/kg rbTNFα treatments. 
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Table 2-6 Plasma metabolites and hormones, liver triglycerides, and glucose turnover rate 
in early-lactation dairy cows. Values are least squares means ± SEM, n = 10-11. 
 
 Treatments1  P-value2 
Item Control 1.5 µg/kg 3.0 µg/kg SEM C vs. T3 Dose4 
Plasma BHBA, µM 996 1108 1186 154 0.40 0.72 
Plasma glucose, mg/dL 50.8 51.9 51.7 2.l 0.68 0.94 
Plasma insulin, ng/mL 0.28 0.31 0.32 0.07 0.35 0.74 
Plasma NEFA, µM 857 854 757 83 0.62 0.41 
Plasma TG, mg/dL 13.5 12.9 12.4 1.1 0.52 0.73 
Plasma 3-
methylhistidine, µM 
10.2 10.0 12.2 1.7 0.58 0.28 
Liver TG, mg/g protein 769 750 702 106 0.34 0.58 
Glucose turnover rate, 
g/min 
3.73 3.04 3.23 0.35 0.18 0.73 
Glucose turnover rate, 
g/kg dry matter intake 
389 335 480 29 0.32 <0.01 
 
1 Treatments: cows were given 0, 1.5, or 3.0 µg/kg body weight rbTNFα injections daily for the 
first 7 days of lactation, respectively. 
2 No treatment by day interactions were significant. 
3 Contrast between Control and rbTNFα treatments. 
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Table 2-7 Health disorders in early-lactation dairy cows during the experimental period. 
 
 Treatments1  
Item2 Control 1.5 µg/kg 3.0 µg/kg Total 
Ketosis 1 3 3 7 
Subclinical mastitis 1 0 2 3 
Respiratory distress 0 0 2 2 
Metritis 1 0 0 1 
Milk fever 0 0 1 1 
Fever 0 0 2 2 
≥ 1 event (fever excluded) 2 3 7 12 
 
1 Treatments: cows were given 0, 1.5, or 3.0 µg/kg body weight rbTNFα injections daily for the 
first 7 days of lactation, respectively. There were 11 cows at risk in each treatment. 
2 Ketosis was recorded when the urine ketone dipstick test (Ketostix; Bayer Corp. Diagnostics 
Division, Elkhart, IN) detected acetoacetate > 80 mg/dL on any day or > 40 mg/dL for 2 
consecutive days. Fever designates that a cow had arectal temperature greater than 39.4°C. 
Other health disorders were diagnosed according to the guidelines by Kelton et al. (1998). 
Fever was excluded from the summary data because of th  possibility that it was a direct 
response to treatment rather than a sign of infection. 
 
 74
Figure 2-1 Plasma concentrations of TNFα and haptoglobin during 7 days of rbTNFα or 
Control administration. (A) Plasma TNFα tended to be increased by rbTNFα treatments (P = 
0.09), but no difference was detected between 1.5 and 3.0 µg/kg rbTNFα treatments (P = 0.19). 
(B) Haptoglobin differed between rbTNFα treatments and Control (P = 0.01), but not between 





Figure 2-2 Composite plasma concentration of anti-inflammatory eicosanoids during the 
first 5 days of rbTNFα or Control administration.  The total anti-inflammatory eicosanoid 
concentration represents the sum of resolvin D1 and D2, protectin, lipoxin A4, 7-maresin 1, 9-
oxoODE, and 13-oxoODE concentrations (Sordillo et al., 2009). The 3.0 µg/kg dose tended to 
differ from the 1.5 µg/kg rbTNFα dose (P = 0.08), but no overall rbTNFα was detected (P = 
0.22). A tendency for a dose by time interaction was also observed (P = 0.06), with a significant 







Figure 2-3 Hepatic mRNA abundance of TNFα and protein abundance of key mediators 
involved in inflammatory pathways. Liver samples were collected after 7 days of rbTNFα or 
Control administration. (A) Hepatic TNFα transcript abundance was increased by 3.0 vs. 1.5 
µg/kg rbTNFα treatments (P = 0.02), but did not differ between rbTNFα treatments and Control 
(P = 0.73). (B) Western blot images are shown for 6 cows along with densitometry data from 
analysis of all samples for hepatic IκBα (37 kDa), TNFα (17 kDa), and total and phosphorylated 
c-Jun (39 kDa). There was a tendency for treatment by parity interaction (P = 0.07) for IκBα, 
reflecting increased (P = 0.04) IκBα abundance by rbTNFα treatment in primiparous cows (data 
not shown). No treatment effects (P > 0.10) were observed for hepatic TNFα, c-Jun, or relative 
c-Jun phosphorylation. (C): Parity significantly affected hepatic IκBα (P = 0.02), TNFα (P = 
0.04), and relative c-Jun phosphorylation (P = 0.04). Values are means ± SEM, n = 10-11 (A and 





Figure 2-4 Hepatic abundance of transcripts involved in lipid metabolism (A) and 
gluconeogenesis (B). Liver samples were collected after 7 days of rbTNFα or Control 
administration. Differences were observed between rbTNFα treatments and Control (P < 0.01), 
and between 1.5 and 3.0 µg/kg rbTNFα treatments (P = 0.04) for CPT1a. No treatment effects (P 
> 0.10) were detected for ApoB, AGPAT1, PCK1, or PC. AGPAT1: 1-acylglycerol-3-phosphate 
O-acyltransferase 1; ApoB: apolipoprotein B; CPT1a: mitochondrial carnitine 
palmitoyltransferase 1A; PC: pyruvate carboxylase; PCK1: phosphoenolpyruvate carboxykinase 
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The objective of this study was to evaluate effects of chromium propionate (CrPr), 
rumen-protected lysine and methionine (RPLM), or both on metabolism, neutrophil function, and 
adipocyte size in lactating dairy cows (38 ± 15 days in milk). Forty-eight individually fed 
Holstein cows (21 primiparous, 27 multiparous) were st atified by calving date in 12 blocks and 
randomly assigned to 1 of 4 treatments within block. Treatments were control, CrPr (8 mg/d Cr, 
KemTRACE brand Chromium Propionate 0.04%, Kemin Industries, Inc.), RPLM (10 g/d lysine 
and 5 g/d methionine intestinally available, from LysiPEARL and MetiPEARL, Kemin 
Industries, Inc.), or CrPr plus RPLM. Treatments were f d for 35 d; blood plasma samples were 
collected on d 21 and 35 of treatment, and blood neutrophils were isolated from 24 cows for 
analysis of tumor necrosis factor α (TNFα) and interleukin 1β (IL-1β) transcript abundance in the 
basal state and after 12 h of lipopolysaccharide (LPS) activation. Tailhead subcutaneous adipose 
tissue samples were collected on d 35 for measurement of adipocyte size. Plasma glucose, 
NEFA, and glucagon concentrations were unaffected by treatments, whereas plasma insulin 
concentration was increased (P = 0.03) by RPLM. Basal TNFα transcript abundance in 
neutrophils was not affected (P > 0.10) by treatment, but basal IL-1β transcript abundance was 
decreased (P = 0.05) by RPLM and tended to be increased by CrPr(P = 0.08). After LPS 
activation, CrPr increased (P = 0.02) neutrophil TNFα transcript abundance. In addition, RPLM 
× parity interactions (P < 0.01) were detected for both TNFα and IL-1β abundance after LPS 
activation, reflecting enhanced responses in primiparous cows and attenuated responses in 
multiparous cows supplemented with RPLM. Adipocyte size was not affected by treatment. 
Supplemental CrPr and RPLM had minimal effects on metabolism when fed for 35 d near peak 
lactation, but may modulate innate immune function in lactating dairy cows. 
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 Introduction 
Chromium is a nutrient that can influence animal metabolism. Supplementation of Cr in 
cattle increased milk production (Hayirli et al., 2001; McNamara and Valdez, 2005; Smith et al., 
2005), improved glucose clearance and insulin sensitivity (Bunting et al., 1994; Spears et al., 
2012; Sumner et al., 2007), reduced lipolysis (Besong, 1996; Bryan et al., 2004), altered adipose 
tissue metabolism (McNamara and Valdez, 2005), and mo ulated immune response (Burton et 
al., 1993; Burton, 1995; Burton et al., 1996). Although considerable research has been conducted 
with Cr in cattle, only recently has Cr supplementation in cattle diets been permitted by the U.S. 
Food and Drug Administration. Currently, Cr-propionate (CrPr) is the only source of Cr allowed 
for supplementation to cattle, at inclusion rates up to 0.5 mg Cr/kg of diet. By feeding CrPr to 
dairy cows from 21 d prepartum to 35 d postpartum, McNamara and Valdez (2005) increased 
DMI and milk yield in early lactation. Interestingly, they also observed that CrPr dramatically 
increased adipose tissue lipogenesis compared to that f controls in the postpartum period. 
Collectively, these results indicate that CrPr may improve production by modulating metabolism 
of lactating cows. 
To improve the performance and productive efficiency of lactating cows, first limiting 
AA such as rumen-protected lysine and methionine (RPLM) have been commonly supplemented 
(Berthiaume et al., 2006; Chilliard and Doreau, 1997; Leonardi et al., 2003). A recent meta-
analysis (Patton, 2010) indicated that feeding rumen-protected methionine increased milk protein 
content and yield and slightly increased milk yield across 35 studies in the literature. However, 
little research has been conducted to determine effects of RPLM on glucose or lipid metabolism 
or immune function in dairy cows. Enhanced metabolic and immune function may contribute to 
improved milk production. 
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Currently, there are no reports regarding the interaction between CrPr and RPLM 
supplementation in dairy cows. We hypothesized that supplementation of both may generate 
effects superior to supplementing either one alone, in part because enhanced milk production in 
response to CrPr would increase essential AA requirments. Therefore, the objective of this 
study was to determine if CrPr and RPLM supplementation affects neutrophil function, 
adipocyte size, or intermediary nutrient metabolism n dairy cows near peak lactation. 
 
 Materials and Methods 
The Kansas State University Institutional Animal Care nd Use Committee approved all 
experimental procedures. Production responses to these treatments are reported in a companion 
paper (Vargas-Rodriguez et al., 2014). 
 
 Design and Treatments  
Forty-eight individually fed Holstein cows (21 primiparous, 27 multiparous, 38 ± 15 DIM, 
mean ± SD) were stratified by calving date in 12 blocks and randomly assigned to 1 of 4 
treatments within block. Treatments were control, CrPr (8 mg/d Cr in the form of 20 g/d 
KemTRACE Chromium Propionate 0.04%, Kemin Industries, Inc., Des Moines, IA), RPLM (10 
g/d lysine and 5 g/d methionine, intestinally available), or both (CrPr+RPLM). The RPLM 
supplement was composed of 48.8 g/d of LysiPEARL and 15.3 g/d of MetiPEARL (Kemin 
Industries, Inc.). Treatments were premixed with ground corn and top-dressed at 200 g/d for 35 
d. All cows were fed once daily (1600 h) for ad libitum intake of a diet formulated to meet NRC 
(2001) nutrient requirements (Table 1). Analysis by the Cornell Net Carbohydrate and Protein 
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System version 6.1 (NDS version 3, Ruminant Management & Nutrition, Reggio Emilia, Italy) 
estimated metabolizable Met supply at 47 g/d (2.03% of MP) and metabolizable Lys supply at 
148 g/d (6.38% of MP) with 22 kg/d DMI in the control diet. The RPLM supplement was 
predicted to result in Lys and Met supplies of 6.77% and 2.23% of MP, respectively.  
 
 Plasma Samples 
On d 21 and 35 (1430 h), approximately 14 mL of blood was collected from all cows 
from the coccygeal vessels into 2 evacuated tubes, one containing K3-EDTA (for analyses of 
NEFA, glucagon, insulin, leptin, and adiponectin) ad the other containing potassium oxalate 
with sodium fluoride (for analysis of glucose) as a glycolytic inhibitor (Vacutainer, Becton 
Dickinson, Franklin Lakes, NJ). Samples were centrifuged at 2,000 × g for 15 min immediately 
after sample collection, and plasma was harvested and frozen at −20°C until analysis. Plasma 
aliquots for glucagon analysis were added to tubes containing benzamidine (50 mM final 
concentration; Sigma-Aldrich Chemical Co., St Louis, MO) as a protease inhibitor. Plasma was 
analyzed for NEFA using an enzymatic colorimetric procedure (NEFA-HR, Wako Chemicals 
USA, Richmond, VA), glucose by a colorimetric kit (Autokit Glucose; Wako Chemicals USA), 
glucagon by a radioimmunoassay kit (#GL-32K Millipore Corp., Billerica, MA), and insulin by a 
bovine-specific sandwich ELISA (#10-1201-01, Mercodia AB, Uppsala, Sweden).  
Plasma samples collected on d 35 were analyzed for leptin and adiponectin protein 
abundance by Western blot. Plasma samples (1 µL) were diluted with 19 µL Laemmli sample 
buffer (Bio-Rad, Richmond, CA). The homogenate was heated at 90°C for 5 min, cooled and 
loaded onto a 4-20% Tris-HCl gel for electrophoresis. Samples were separated by SDS-PAGE 
and dry-transferred onto nitrocellulose membranes (iBlot, Invitrogen, Carlsbad, CA). 
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Membranes were blocked for 2 h in blocking buffer (5% dry milk in Tris-HCl buffer, pH 7.5, 
with 0.05% Tween 20). After incubation with blocking buffer, the membranes were washed 3 
times for 5 min each with washing buffer (phosphate-buffered saline, pH 7.5, containing 0.05% 
Tween 20). Membranes were then incubated with primary antibodies (1:500) against leptin (sc-
8325, Santa Cruz Biotechnology Inc., Santa Cruz, CA) and adiponectin (A6354, Sigma-Aldrich 
Co, St. Louis, MO) overnight at 4°C. After washing, a secondary antibody (sc-2313, Santa Cruz 
Biotechnology) diluted 1:10,000 was incubated for 1 h at room temperature. Immunodetection 
was performed by chemiluminescence (West-Dura; Thermo Scientific, Waltham, MA) and bands 
quantified by scanning densitometry (ChemiDoc-It Imaging System; UVP Inc., Upland, CA).  
 
 Neutrophil Isolation 
On d 21 and 35 (0700 h), 50 mL of blood was obtained by jugular venipuncture from 6 
blocks of the cows for isolation of neutrophils. Blood was collected in 50-mL tubes (Becton 
Dickinson) with 0.75 mL of heparin (1,000 units/mL, Acros Organics Inc., Fair Lawn, NJ). 
Blood was placed on ice for transport to the lab (< 60 min) and then 20 mL of whole blood was 
combined with 20 mL of Ficoll-Paque PLUS (GE Healthcare, Pittsburgh, PA) and centrifuged at 
800 × g for 50 min at 4°C. Centrifugation separated the blood into 6 distinct bands: plasma, 
monocytes, isolation media, neutrophils, more isolati n media, and the red blood cell pellet. The 
top three layers (plasma, monocytes, and isolation media) were removed, and neutrophils were 
collected and washed with Ca2+/Mg2+ free Hank’s balanced salt solution (Sigma-Aldrich 
Chemical Co.) 3 times. Isolated neutrophils from each cow were split into 2 samples; one sample 
was immediately frozen for subsequent analysis of basal neutrophil status. The remaining 
neutrophils were suspended in Dulbecco's modified Eagle's medium with 10% fetal bovine 
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serum and 1% penicillin/streptomycin (Sigma-Aldrich C emical Co.) and incubated with 1 
µg/mL lipopolysaccharide (LPS, from E. coli O55:B5, Sigma-Aldrich Chemical Co.) for 12 h. 
Cells were frozen at −80°C until analysis of transcript abundance of tumor necrosis factor α 
(TNFα) and interleukin 1β (IL-1β) in the basal state or after 12 h of LPS activation. 
 
 Transcript Abundance 
Total RNA was extracted from neutrophils using a commercial kit (RNeasy Lipid Tissue 
Mini Kit, Qiagen Inc., Valencia, CA) according to the manufacturer's instructions. Two 
micrograms of total RNA was used as template for the reverse transcriptase reaction using 
random primers (High-Capacity cDNA RT Kit, Applied Biosystems, Foster City, CA). 
Quantitative real-time PCR (qPCR) was performed in uplicate on 96-well plates with 1/20 of 
the cDNA product in the presence of 200 nmol/L gene-sp cific forward and reverse primers with 
real-time SYBR green fluorescent detection using SYBR Green Premix reagent (7500 Fast Real-
Time PCR System, Applied Biosystems). Primers were d signed 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast) using the following GenBank accessions to 
generate these primer sequences (all 5′–3′):  TNFα (NM_173966.3), forward 
AAGTAACAAGCCGGTAGCCCA, reverse CTTCCAGCTTCACACCGTTG; IL-1β 
(NM_174093.1), forward CACGTGGGCTGAATAACCCCGA, revers  
AGGCAGTCGGGCATGGATCAGA; ribosomal protein subunit 9 (RPS9) (NM_001101152.2), 
forward GAACAAACGTGAGGTCTGGAGG, reverse TTACCTTCGAACAGACGCCG. All 
sample values were normalized against RPS9 (Mamedova et al., 2010), and relative gene 
expression was quantified by using the 2−∆Ct method. 
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 Adipose Tissue Biopsy 
On d 35, tailhead subcutaneous adipose tissue samples were collected from all cows. At 
the time of sampling, the site was shaved and aseptically prepared. The tailhead was then 
anesthetized with 2 mL of 2% lidocaine hydrochloride. An incision of 2 to 3 cm in length was 
made between the tailhead and the tuber ischii, and adipose tissue was collected as described 
previously (Smith and McNamara, 1990). Incisions were closed by a skin stapler (Oasis 
Disposable Skin Stapler, Med-Vet International, Mettawa, IL). Tissue samples were trimmed to 
eliminate contaminating tissue and were cut into small pieces (approximately 1 cm3). One 
sample from each cow was embedded in Optimal Cutting Temperature compound (OCT, Tissue-
Tek, The Netherlands) and was frozen at -80°C for subsequent analysis of adipocyte size. 
 
 Adipocyte Morphology 
Adipose tissue cryosections (14 µm) were prepared on a cryostat (Microm HM550, 
Thermo Fisher Scientific Inc., Kalamazoo, MI) and mounted on SuperFrost slides (Thermo 
Fisher Scientific Inc). Tissue sections were fixed in 4% paraformaldehyde for 10 min, rinsed 
twice with phosphate buffered saline, and coverslipped. Representative images were captured 
using a Nikon Eclipse TI-U inverted microscope with 10× working distance magnification 
(Nikon Instruments Inc., Melville, NY). Five representative photomicrographs per animal were 
captured using a Nikon DS-QiMc digital camera (Nikon Instruments Inc.). All the adipocytes in 
each photomicrograph and at least 150 adipocytes per ample were analyzed for adipocyte cross-




 Calculations and Statistical Analysis  
An insulin sensitivity measure, revised quantitative insulin sensitivity check index 
(RQUICKI) was calculated as (Holtenius and Holtenius, 2007): RQUICKI = 1/[log(Gb) + log(Ib) 
+ log(NEFAb)], where Gb = glucose (mg/dL), Ib = insulin (µU/mL), and NEFAb = NEFA 
(mmol/L), such that a lower RQUICKI indicates greater insulin resistance. Insulin, determined in 
ng/mL units, was converted to µU/mL units by assuming an activity of 25.1 µU/ng (JAMA, 
2010). The distribution of adipocyte area values within each cow (from 5 randomly selected 
cows) was plotted to assess the normality of the population. In contrast to some previous reports 
demonstrating bimodal adipocyte populations in relatively obese animals (Cruz et al., 2012), 
adipocyte populations within animal were unimodal in this study. However, distributions were 
right-skewed because of small numbers of very large dipocytes. Therefore, median adipocyte 
area from each cow was used instead of the mean value for further analysis.  
One cow receiving CrPr+RPLM developed severe mastitis on d 20 of treatment and was 
subsequently removed from the study; no data were coll cted or analyzed for this cow. Data 
were analyzed using ProcMIXED of SAS (version 9.2; SAS Institute Inc., Cary, NC) to assess 
the fixed effects of day, CrPr, RPLM, parity, and all interactions, and the random effect of block. 
With the exception of CrPr × RPLM, interactions were removed from models when P > 0.30. 
Data for TNFα and IL-1β transcript abundance in neutrophils were log-transformed for analysis 
and reported values are back-transformed. Repeated measures over time within cow were 
modeled with an autoregressive (AR[1]) covariance structure. Denominator degrees of freedom 
were estimated using the Kenward-Rogers method. Values were deemed outliers and omitted 
from analysis when Studentized residuals were > 3.5 or < -3.5. Significance was declared at P ≤
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0.05 and trends at 0.05 < P ≤ 0.10. Treatment means were separated with pair-wise t-tests when 
interactions were significant. 
 
 Results 
 Plasma Data 
Plasma metabolite and hormone concentrations are shown in Table 2. Glucose and NEFA 
concentrations were not affected (P > 0.10) by RPLM or CrPr. Compared with d 21, glucose 
tended to be decreased (50.5 vs. 53.1 ± 1.5 mg/dL, P = 0.10) and NEFA were decreased (223 vs. 
342 ± 22 µM, P < 0.001) on d 35. Insulin was unaffected (P > 0.10) by CrPr, but was increased 
(P = 0.03) by RPLM, and was greater on d 35 compared with d 21 (311 vs. 259 ± 23 pg/mL, P = 
0.04). Although glucagon was not affected (P > 0.10) by CrPr or RPLM, there was an interaction 
of RPLM × day (P = 0.04), reflecting increased (P = 0.05) glucagon concentration (173 v. 159 ± 
5.6 pg/mL) by RPLM on d 35; no difference (P = 0.53) was detected on d 21. The RQUICKI 
measure of insulin sensitivity did not show treatment ffects (P > 0.10), but tended to be 
increased on d 35 compared with d 21 (0.569 vs. 0.536 ± 0.014, P = 0.08). Primiparous cows 
tended to have lesser RQUICKI values than multiparous cows (0.536 vs. 0.570 ± 0.014, P = 
0.07).  
Plasma leptin and adiponectin protein abundance on d 35 is shown in Figure 1. Plasma 
leptin protein abundance (Figure 1A) tended to be increased (P = 0.09) by RPLM, but was 
unaffected (P > 0.10) by CrPr. In addition, there was a tendency for a CrPr × parity interaction 
(P = 0.08), reflecting decreased (P = 0.04) leptin abundance by CrPr in multiparous cows, but 
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not (P = 0.53) in primiparous cows (Figure 1B). Plasma adiponectin protein abundance (Figure 
1C) was not altered (P > 0.10) by treatments. 
 
 Neutrophil Transcript Abundance 
Basal TNFα transcript abundance (Figure 2A) in neutrophils wa not affected (P > 0.10) 
by treatment or day. After LPS activation, TNFα transcript abundance increased compared with 
non-stimulated controls, and tended (P = 0.07) to be greater in cells collected on d 21 compared 
with d 35. Dietary CrPr increased (P = 0.02) TNFα abundance in LPS-activated neutrophils 
(Figure 2B). There was a RPLM × parity interaction (P < 0.01), reflecting increased TNFα 
transcript abundance in LPS-stimulated neutrophils from primiparous cows (P < 0.01) and a 
tendency for decreased TNFα in multiparous cows (P = 0.07) in response to RPLM (Figure 2C).  
Basal IL-1β transcript abundance in neutrophils was decreased (P = 0.05) by RPLM, and 
tended to be increased by CrPr ( = 0.08, Figure 3A). Basal IL-1β transcript abundance was 
increased between d 21 and d 35 (P = 0.01), and was greater (P = 0.04) in primiparous cows than 
multiparous cows (12.2 vs. 2.7 ± 7.77 arbitrary units). After LPS activation, IL-1β transcript 
abundance increased dramatically, but no treatment or day effects (P > 0.10) were observed 
(Figure 3B). However, there was a RPLM × parity interaction (P < 0.01), reflecting increased IL-
1β transcript abundance in primiparous cows (P = 0.03) and decreased IL-1β in multiparous 
cows (P = 0.01) in response to RPLM (Figure 3C). 
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 Adipocyte Morphology 
Figure 4A depicts a representative photomicrograph of an adipose tissue cross-section. 
Tailhead subcutaneous adipocyte cross-sectional are was not affected (P > 0.10) by RPLM or 
CrPr (Figure 4B), but was greater (P = 0.02) in primiparous compared with multiparous cows 
(4,942 vs. 3,577 ± 427 µm2). Median adipocyte cross-sectional area was positively correlated 
with d 35 BCS (P < 0.001, Figure 5), but not BW (P > 0.10).  
 
 Discussion 
In this study, CrPr supplementation did not affect plasma glucose, NEFA, insulin, or 
glucagon concentrations in lactating cows. Most studies evaluating the effects of Cr 
supplementation on dairy cattle metabolism have been conducted in the periparturient period, 
and effects on circulating hormones and metabolites in lactating animals have been limited. 
Hayirli et al. (2001) reported that supplementing peri arturient cows with 0, 0.03, 0.06, and 0.12 
mg/kg BW0.75 of Cr as chromium-L-methionine (Cr-Met) decreased plasma insulin but did not 
affect plasma glucose, glucagon, or NEFA concentrations in early lactation. Smith et al. (2008) 
reported that supplementation of 0.03 or 0.06 mg/kg BW0.75 of Cr as Cr-Met had no effects on 
these plasma concentrations in early lactation despite ome alterations in late gestation. 
Interestingly, we found that RPLM supplementation increased plasma insulin concentration. 
Essential AA have long been considered to be physiologic stimuli for insulin secretion in humans 
(Floyd et al., 1966), but few studies have focused on the influence of dietary AA 
supplementation on insulin concentrations in dairy cows. By feeding a rumen-protected 
methionine product, Blum et al. (1999) observed increased plasma insulin concentrations in 
lactating cows within 5 d of supplementation. In the present study, although insulin was 
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significantly increased by RPLM, this increase was not likely of great consequence for the 
metabolism and performance of animals because othermetabolites were unaffected. 
One important characteristic of Cr is its modulatory effect on insulin sensitivity. It has 
been established that Cr supplementation alleviates nsulin resistance, enhances glucose 
tolerance, and improves metabolism in obese or type 2 diabetic subjects (Cefalu et al., 2010; Kim 
et al., 2011; Wang and Cefalu, 2010). Although the mode of action is not precisely known, Cr 
has been shown to enhance insulin binding, insulin receptor abundance, and pancreatic β-cell 
sensitivity (Wang and Cefalu, 2010). A recent paper also proposed that Cr improves insulin 
action by activating glucose transporter 4 trafficking and enhancing insulin-stimulated glucose 
transport in adipocytes (Chen et al., 2006). In the bovine, Sumner et al. (2007) reported that CrPr 
supplementation improved glucose tolerance in growing Holstein heifers. There has also been 
interest in effects of Cr supplementation on insulin sensitivity in the periparturient period (Sano 
et al., 1993), when insulin resistance typically occurs (Bell and Bauman, 1997). Subiyatno et al. 
(1996) found that supplementation of 0.5 mg Cr/kg DM beginning 6 wk prepartum increased 
insulin sensitivity in primiparous but not multiparous dairy cows at 2 wk before parturition. 
Hayirli et al. (2001) reported that Cr-Met supplementation from 21 d prepartum to 28 d 
postpartum improved glucose tolerance and insulin responsiveness measured at 28 d postpartum 
in multiparous dairy cows. Therefore, by modulating i sulin action, Cr may have significant 
implications for health and performance of lactating dairy cows. In the current study, we used 
RQUICKI to estimate insulin sensitivity (Holtenius and Holtenius, 2007). We found that 
RQUICKI tended to be lesser on d 21 compared with d 35, which is consistent with insulin 
resistance in early lactation. Furthermore, RQUICKI tended to be lesser in primiparous 
compared with multiparous cows, indicating that in this study first-lactation heifers were 
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relatively more insulin resistant. However, RQUICKI was not affected by treatments, suggesting 
that CrPr and RPLM did not alter insulin sensitivity. 
Neutrophils are the first line of immune defense in dairy cows. Upon maturation, 
neutrophils are released into circulation and play ke  roles for immune surveillance and defense 
against pathogens (Burton and Erskine, 2003). Impaired neutrophil trafficking, phagocytosis, or 
killing directly contribute to immunosuppression and i creased disease incidence in early-
lactation cows (Kehrli et al., 1989). Among other functions, neutrophils serve as a significant 
source of pro-inflammatory cytokines, such as TNFα and IL-1β (Sohn et al., 2007). These 
cytokines are critical in activating and coordinatig mmune responses. As a cell wall component 
of Gram-negative bacteria, LPS frequently has been us d to stimulate immune cells; the capacity 
of these activated cells to produce pro-inflammatory cytokines can be used to assess the 
competence of these immune cells (Mani et al., 2012).  
In this study, we evaluated the impact of CrPr and RPLM supplementation on neutrophil 
function by determining TNFα and IL-1β transcript abundance in neutrophils in the basal state 
and after 12 h of LPS activation. We found that CrPr did not affect basal TNFα transcript 
abundance, but significantly increased its abundance fter LPS activation. These results suggest 
that CrPr supplementation may improve innate immune response upon activation. Several studies 
have highlighted the role of Cr in bovine immunity. Burton et al. (1993) reported that Cr 
supplementation at 0.5 mg Cr/kg DM from 6 wk prepartum through 16 wk postpartum increased 
antibody responses to ovalbumin administration and mitogen-stimulated blastogenesis of blood 
monocytes in lactating cows. In addition, TNFα and IL-2 production from mitogen-stimulated 
monocytes was significantly decreased for cows supplemented with Cr compared with controls, 
particularly around peak lactation (Burton et al., 1996).  
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Interestingly, RPLM increased LPS responsiveness of neutrophils from primaparous 
cows but decreased responsiveness of neutrophils from multiparous cows, based on both TNFα 
and IL-1β results. The reasons underlying the discrepant responses to RPLM supplementation in 
primiparous and multiparous cows are unclear. We also observed that basal IL-1β transcript 
abundance in neutrophils was decreased by RPLM and tended to be increased by CrPr. Recent 
research has suggested that AA play an important role in immune modulation by regulating 
immune cell activation, proliferation, antibody production, and cytokine production, whereas 
dietary AA deficiency directly impairs immune function of animals (Li et al., 2007). For 
example, lysine deficiency limits cytokine synthesis and lymphocyte proliferation, and impairs 
immune responses in chickens (Konashi et al., 2000). Methionine supplementation markedly 
enhanced several key aspects of innate and humoral immune responses in chickens infected with 
virus (Li et al., 2007). Although little research has directly assessed the effects of these AA on 
bovine inflammation and immune function, the interaction between these nutrients and immunity 
warrants further research.  
Several studies have been conducted in an attempt to modulate lipolysis in lactating dairy 
cows by dietary manipulations (Baumgard et al., 2002; McNamara and Valdez, 2005; Yuan et 
al., 2012). For example, conjugated linoleic acid (CLA, trans-10,cis-12 isomer) decreased milk 
fat synthesis in lactating cows and reduced body fat accretion in growing animals by decreasing 
de novo lipogenesis (Bauman et al., 2000). Recently, Akter et al. (2011) reported that 
supplementation of dairy cows with 100 g of CLA/d (about 6% each of cis-9,trans-11 and trans-
10,cis-12 isomers) for the first 100 d of lactation considerably decreased adipocyte sizes in 
different fat depots. This finding supports the concept that adipocyte size is sensitive to altered 
rates of lipogenesis or lipolysis in dairy cows (McNamara, 1991). By feeding 10 mg/d Cr as CrPr 
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to dairy cows from 21 d prepartum to 35 d postpartum, McNamara and Valdez (2005) 
dramatically increased adipose tissue lipogenesis postpartum, but did not affect rates of lipolysis. 
In the present study, however, we did not detect effects of CrPr or RPLM on subcutaneous 
adipocyte size. Interestingly, adipocyte size was po itively correlated with BCS, supporting the 
observation that fatter cows typically have greater dipocyte size (McNamara, 1991). In addition, 
we found that adipocyte size was greater in primiparous than multiparous cows (4,942 vs. 3,577 
± 427 µm2, P = 0.02), which is consistent with the observation hat first-lactation heifers tended 
to have greater BCS than multiparous cows (2.94 vs. 2.70 ± 0.085, P = 0.07).  
We also measured the protein abundance of several ky hormones secreted from 
adipocytes to assess adipose tissue endocrine status. Leptin is primarily secreted by adipocytes 
and plays a central role in the regulation of feed intake, energy metabolism, and body condition 
(Block et al., 2003; Ingvartsen and Boisclair, 2001). In dairy cows, plasma leptin concentrations 
have been shown to be positively related to body fatness (Kokkonen et al., 2005; Reist et al., 
2003). In this study, however, plasma leptin protein abundance was not correlated with BCS (P = 
0.53, r2 = 0.009, data not shown). Leptin abundance tended to be increased by RPLM, and was 
decreased by CrPr in multiparous cows. Adiponectin, another adipokine secreted by adipose 
tissue, plays a key role in glucose and lipid metabolism (Kadowaki and Yamauchi, 2005). 
Paradoxically, despite being produced in adipose tissue, adiponectin was negatively correlated to 
body fatness in humans (Ahima, 2006; Kadowaki and Yamauchi, 2005). In dairy cows, however, 
a previous study did not detect a relationship betwe n plasma adiponectin concentrations and 
BCS (Raddatz et al., 2008). Interestingly, we found a negative correlation (P = 0.02, r2 = 0.16, 
data not shown) between plasma adiponectin protein abu dance and BCS, which agrees with the 
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human data mentioned above. Here, we did not find effects of CrPr or RPLM on adiponectin 
protein abundance. 
Taken together, our results indicate that supplemental CrPr (8 mg/d Cr), RPLM (10 g/d 
Lys and 5 g/d Met), or both provided for 35 d had mini al effects on metabolism and adipocyte 
size, but may modulate neutrophil function in lactating dairy cows. Neutrophil inflammatory 
responses to pathogen-associated molecules may be enhanced by CrPr supplementation and 
RPLM can also influence these responses in a parity-dependent manner. 
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Table 3-1 Ingredient and nutritional composition of the basal diet 
Ingredient % of DM 
Corn silage 31.5 
Alfalfa hay 23.4 
Wet corn gluten feed1 6.8 
Ground corn 23.1 
Whole cottonseed 4.6 
Mechanically extracted soybean meal2 2.1 
Solvent extracted soybean meal 5.1 
Ca salts of long-chain fatty acids3 0.8 
Micronutrient premix4 2.6 
  
Nutrient, % as-fed 
 







Ether extract 3.1 
GE, Mcal/kg 4.11 
DE6, Mcal/kg 3.34 
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ME7, Mcal/kg 2.92 
NEL
8, Mcal/kg 1.87 
Model-predicted ME9, Mcal/kg 2.50 
 
1SweetBran, Cargill Inc., Blair, NE 
2Soy Best, Grain States Soya, West Point, NE 
3Megalac-R, Church & Dwight Co, Princeton, NJ  
4Premix consist of 45.1% limestone, 32.2% of sodium bicarbonate, 6.4% 
magnesium oxide, 5.2% sodium chloride, 5.2% vitamin E premix (44 
IU/g), 0.45% vitamin A premix (30 IU/g), 0.19% vitamin D premix (30 
IU/g), 2.1% 4-Plex (Zinpro Corp., Eden Prairie, MN; contains 2.58% Zn, 
1.48% Mn, 0.90% Cu, 0.18% Co, 8.21% Met, and 3.80% Lys), 0.96% 
selenium premix (600 ppm Se), 0.45% Zinpro 100 (Zinpro Corp.; 
contains 10% Zn and 20% Met), 0.03% ethylenediamine dihydriodide 
premix (3.65% I), 0.88% Kallsil (Kemin Industries), and 0.88% Myco 
CURB (Kemin Industries). 
5forage NDF 
6DE = (Gross energy intake – gross energy in feces)/DMI. 
7ME = [1.01 × (DE, Mcal/kg) - 0.045] + 0.0046 × (EE, % -3). 
8NEL = 0.703 × ME (Mcal/kg) – 0.19 + [(0.097 × ME, Mcal/kg + 
0.19)/97] × [EE, % -3].  
9ME predicted by CNCPS 6.1 (NDS version 3, Ruminant Management & 
Nutrition, Reggio Emilia, Italy). 
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Table 3-2 Effects of chromium propionate (CrPr) and rumen-protected lysine and methionine 
(PRLM) on plasma metabolites and hormones in lactating dairy cows on d 21 and 35 of dietary 
treatment. Values are least squares means across d 21 and 35. 
 
 Treatment  P value1 
Item Control CrPr RPLM CrPr+RPLM SEM CrPr RPLM Day 
Glucose, mg/dL 51.4 51.9 52.2 51.8 2.0 0.96 0.83 0.10 
Insulin, ng/mL 0.259 0.247 0.273 0.357 0.032 0.20 0.03 0.04 
NEFA, µM 314 292 287 238 38 0.34 0.28 <0.001 
Glucagon2, ng/mL 0.163 0.173 0.169 0.173 0.006 0.30 0.38 0.27 
RQUICKI3 0.522 0.533 0.534 0.533 0.015 0.68 0.64 0.08 
 
1 No interactions were significant except as noted for glucagon. 
2 RPLM × day interaction (P = 0.04). Glucagon concentration was increased by RPLM on d 35 
(0.173 vs. 0.159 ± 0.006 ng/mL, P = 0.05), but not on d 21 (0.173 vs. 0.169 ± 0.006 ng/mL, P = 
0.53). 
3 Revised quantitative insulin sensitivity check index (Holtenius and Holtenius, 2007).  
 
 
Figure 3-1 Plasma leptin and adiponectin protein abundance 
supplemented with control, chromium propionate (CrPr), rumen
methionine (RPLM), or both (CrPr+RPLM).
dietary treatment, and protein abundance was measurd by Western blot. 
tendency for increased leptin abundance in response to RPLM (
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Figure 3-2 Neutrophil transcript abundance of tumor necrosis factor α (TNFα) in the basal 
state or after 12 h of lipopolysaccharide (LPS, 1 µg/mL) activation. Cows were supplemented 
with control, chromium propionate (CrPr), rumen-protected lysine and methionine (RPLM), or 
both (CrPr+RPLM). Neutrophils were isolated from blood samples collected on d 21 and 35 of 
dietary treatments. (A): Basal TNFα abundance was not affected by RPLM (P = 0.59), CrPr (P = 
0.82), or RPLM × CrPr (P = 0.53). There was a tendency for a CrPr × day interac ion (P = 0.09), 
but CrPr did not affect (P > 0.10) TNFα transcript abundance on either d 21 or 35 (data not 
shown). (B): LPS-activated TNFα transcript abundance was increased (P = 0.02) by CrPr 
supplementation but there were no effects for RPLM (P = 0.14) or RPLM × CrPr (P = 0.76); 
TNFα transcript abundance tended to be greater (P = 0.07) on d 21 compared with d 35 (data not 
shown). (C): LPS-activated TNFα transcript abundance was affected by an RPLM × parity 
interaction (P < 0.01), reflecting increased TNFα transcript abundance in primiparous cows (P < 
0.01) and a tendency for decreased TNFα transcript abundance in multiparous cows (P = 0.07) in 


































































































Figure 3-3 Neutrophil transcript abundance of interleukin 1β (IL-1β) in the basal state or 
after 12 h of lipopolysaccharide (LPS, 1 µg/mL) activation. Cows were supplemented with 
control, chromium propionate (CrPr), rumen-protected lysine and methionine (RPLM), or both 
(CrPr+RPLM). Neutrophils were isolated from blood samples collected on d 21 and 35 of dietary 
treatments. (A): Basal IL-1β transcript abundance was decreased (P = 0.05) by RPLM, and 
tended to be increased (P = 0.08) by CrPr, but there was no RPLM × CrPr interaction (P = 0.13). 
(B): LPS-activated IL-1β transcript abundance was not affected by RPLM (P = 0.91), CrPr (P = 
0.60), or RPLM × CrPr (P = 0.54). (C): LPS-activated IL-1β transcript abundance was affected 
by a RPLM × parity interaction (P < 0.01), reflecting increased IL-1β transcript abundance in 
primiparous cows (P = 0.03) and decreased IL-1β transcript abundance in multiparous cows (P = 




























































































Figure 3-4 Subcutaneous adipocyte size in lactating dairy cows. Cows were supplemented 
with control, chromium propionate (CrPr), rumen-protected lysine and methionine (RPLM), or 
both (CrPr+RPLM). Adipose tissue samples were colleted from the tailhead on d 35 of dietary 
treatment for assessment of median (≥ 150 cells/cow) cross-sectional area of adipocytes. (A): 
there were no effects of RPLM (P = 0.14), CrPr (P = 0.58), or RPLM × CrPr (P = 0.46) on 
adipocyte size. (B): a representative photomicrograph (original magnification 10 ×) of adipose 






























Figure 3-5 Correlation between median cross
and body condition score (BCS, on d 35) in lactating dairy cows.
were collected on d 35 of dietary treatment.
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Chapter 4 - Yeast product supplementation modulated feeding 
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The objective of this study was to assess the effects of supplementing a yeast product 
derived from Saccharomyces cerevisiae on production, feeding behavior, and metabolism in 
transition cows. Forty multiparous Holstein cows were blocked by expected calving date and 
randomly assigned within block to 1 of 4 treatments (  = 10) from 21 d before expected calving 
to 42 d postpartum. Rations were top-dressed with a yeast product (yeast culture plus 
enzymatically hydrolyzed yeast; Celmanax, Vi-COR, Mason City, IA) at the rate of 0, 30, 60, or 
90 g/d throughout the experiment. Dry matter and water intake, feeding behavior, and milk 
production were monitored. Plasma collected on -21, -7, 1, 4, 7, 14, 21, and 35 d relative to 
calving were analyzed for glucose, β-hydroxybutyrate (BHBA), and nonesterified fatty acids 
(NEFA). Data were analyzed using mixed models with repeated measures over time. Pre- or 
postpartum dry matter intake (DMI) and water intake did not differ (P > 0.10) among treatments. 
There were quadratic dose effects (P < 0.05) for prepartum feeding behavior, reflecting 
decreased meal size, meal length, and intermeal interval, and increased meal frequency for cows 
received 30 and 60 g/d of yeast products. Postpartum feeding behavior was unaffected (P > 0.10) 
by treatments. Milk yields were not affected (P > 0.10; 45.3, 42.6, 47.8, and 46.7 kg/d for 0, 30, 
60, and 90 g/d, respectively) by treatments. Tendencies for increased (0.05 < P ≤ 0.10) 
percentages of milk fat, protein, and lactose were d t cted for cows receiving yeast. Yeast 
product increased (P < 0.01) plasma BHBA and tended to decrease (P = 0.06, quadratic dose 
effect) glucose, but did not affect NEFA. Yeast product supplementation during the transition 
period did not affect milk production and DMI, but modulated feeding behavior and metabolism. 
 
Key words: feeding behavior, metabolism, transition cow, yeast  
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 Introduction  
The transition from late gestation to early lactation in dairy cows is characterized by 
dramatic energy requirements for milk synthesis and secretion, inadequate feed intake, and 
substantial metabolic stress (Grummer, 1995). Therefore, the transition period directly 
determines the lactational performance, health, and profitability of dairy cows. Yeast products 
derived from Saccharomyces cerevisiae have been added to diets in an attempt to improve 
ruminal fermentation, feed intake, and milk yield. Dann et al. (2000) reported that yeast culture 
supplementation at 60 g/d from approximately 21 d prepartum to 140 d postpartum increased 
DMI during both the last 7 d prepartum (P = 0.01) and the first 42 d of lactation (P = 0.05) in 
Jersey cows. A recent transition cow study (Ramsing et al., 2009) reported that yeast culture 
supplementation at 57 g/d from approximately 21 d prepartum to 21 d postpartum improved 
prepartum DMI (P < 0.01) and postpartum milk production (P < 0.01). Desnoyers et al. (2009) 
conducted a quantitative meta-analysis using 157 experiments to assess the responses to yeast 
supplementation, and found that yeast products increased rumen pH, DMI, milk yield, and 
tended to increase milk fat content. These data indicate that yeast products may modulate the 
metabolism and improve the production of dairy cows. The objectives of this study were to 
assess whether a yeast product alters milk production, feeding behavior, and biomarkers of lipid 
and glucose metabolism in transition dairy cows. 
  
 Materials and Methods 
The Kansas State University Institutional Animal Care nd Use Committee approved all 
the experimental procedures. 
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 Design and Treatments 
Forty multiparous Holstein transition cows from theKansas State University Dairy Cattle 
Teaching and Research Facility were used in a randomized complete block design. Cows were 
blocked by expected calving date (10 blocks), and romly assigned within block to 1 of 4 
treatments 21 d before their expected calving date. Cows remained on their respective treatments 
through 42 d postpartum. Cows received a yeast product (yeast culture plus enzymatically 
hydrolyzed yeast; Celmanax, Vi-COR, Mason City, IA)at a rate of 0, 30, 60, or 90 g/d. Yeast 
product was administered daily to each cow in the treatment groups by top-dressing and 
manually mixing the premix into the upper part of each TMR. Diets were formulated to meet or 
exceed NRC (2001) requirements (Table 1). Samples of corn silage were collected weekly; all 
other dietary ingredients were collected biweekly and stored at -20°C. Upon study completion, 
feed ingredients were composited monthly for analysis by NIR or wet chemistry by Dairy One 
Forage Laboratory (Ithaca, NY).   
 
 Management of Cows, Data Collection, and Sample Analysis 
Dry cows were moved into the maternity barn approximately 1 wk before entering the 
study. Cows were allowed ad libitum access to the designated treatment rations by an electronic 
gating system (Roughage Intake System, Insentec B.V., Marknesse, The Netherlands). After 
parturition, cows were moved into a tie-stall facility where they remained through 42 d 
postpartum. Individual feed bunks in the tie-stall f cility were suspended from individual load 
cells and bunk weight was monitored continuously by computer. Feed weights and times were 
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stored prior to and immediately after any deviation in bunk weight. Dry cows were fed twice 
daily (1100 and 1800 h), and lactating cows were fed twice daily (1200 and 1900 h). All cows 
were fed for ad libitum intake. All feeding activity, including meal length and size, were 
recorded electronically. As-fed feed intake of each cow was recorded on a daily basis. As-fed 
ration consumption was adjusted for DM content for determination of meal and daily DMI. Dry 
matter percentage was determined for each monthly composited feed ingredient; these values 
were used to determine ration DM for each month. Water was offered ad libitum and individual 
water consumption was measured daily throughout the study. 
Cows were milked 3 times daily in a milking parlor. Milk yields were recorded at each 
milking. Milk samples were collected at each milking on 3 consecutive days each week, and 
were analyzed for concentrations of fat, true protein, lactose (B-2000 Infrared Analyzer; Bentley 
Instruments, Chaska, MN), and urea nitrogen (MUN spectrophotometer, Bentley Instruments). 
Energy-corrected milk yield was calculated as: (0.327 × milk yield) + (12.86 × fat yield) + (7.65 
× protein yield) (Dairy Records Management Systems, 2010). Solids-corrected milk production 
was calculated as: (12.3 × %fat) + (6.56 × %solids-non fat) – (0.0752 × milk yield) (Tyrrell and 
Reid, 1965). Body condition score was evaluated weekly.  
Blood samples were collected on d -21, -14, -7, 1, 4, 7, 21, and 35 relative to calving 
from the coccygeal vessels 1 h prior to feeding. Approximately 20 mL of blood was collected 
into 4 tubes (Vacutainer, Becton Dickinson, Frankli Lakes, NJ, USA): one 7-mL tube 
containing potassium EDTA, one 3-mL tube containing potassium EDTA, one 5-mL tube 
containing heparin, and another 7-mL tube containing potassium oxalate with sodium fluoride as 
a glycolytic inhibitor. Blood samples from the 7-mL potassium EDTA tube and the 7-mL tube 
containing potassium oxalate with sodium fluoride wre centrifuged at 2000 × g for 10 min 
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immediately after sample collection, and plasma washarvested and frozen at -20°C until 
subsequent analysis of glucose, BHBA, and NEFA. Plasma samples were analyzed for NEFA 
using an enzymatic colorimetric procedure (NEFA-HR, Wako Chemicals USA, Richmond, VA), 
glucose by a colorimetric kit (kit #439-90901, Wako Chemicals USA), and BHBA using an 
enzymatic reaction (kit #H7587-58, Pointe Scientific, Inc.). Absorbance was read on a 
spectrophotometer (Powerwave XS, Biotek Instruments, Winooski, VT, USA) and calculations 
were conducted using Gen5 software (Biotek Instruments). Blood collected from the 3-mL 
potassium EDTA tube and the 5-mL tube containing heparin were analyzed for hematology and 
whole blood bactericidal capacity, respectively (reported in Yuan et al., 2014). 
 
 Data and Statistical Analysis 
One cow in the 0 g/d treatment group was removed from the study on d 30 postpartum 
due to difficulty standing up in the tie-stall. Data obtained from this cow prior to removal were 
included in all analyses. Feeding behavior variables w re calculated from logged data that 
included the start and end weights as well as start and end times of meals. Meals were combined 
if intermeal interval was less than 12 min, a criteria used in our previous study (Mullins et al., 
2012) that used the same feeding systems and housing facilities. Data were analyzed using mixed 
models with repeated measures over time. Models incuded the fixed effects of treatment, time, 
and their interaction, and the random effect of cow. Contrast statements were used to assess the 
overall effect of yeast product (control vs. all yeast product treatments), as well as the linear and 
quadratic effects of dose. If treatment by time effcts were significant, slices were used to assess 
effects on specific days. Values were deemed outliers and omitted from analysis when 
Studentized residuals were greater than > |3.0|. After initial outlier removal, the model was 
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repeated and Studentized residuals greater than > |3.5| were deemed outliers. Prepartum and 
postpartum measures were analyzed separately for DMI, water intake, and feeding behavior 
variables. Significance was declared at P ≤ 0.05 and tendencies at 0.05 < P ≤ 0.10. 
 
 Results 
There were no significant differences among groups in prepartum dietary treatment 
length (18.1, 18.8, 17.8, and 17.2 ± 1.32 d for 0, 30, 60, and 90 g/d, respectively; P = 0.86). 
Actual calving dates ranged from 13 d before expected alving to 5 d after expected calving. 
 
 Feed Intake, Water Intake, and Feeding Behavior 
Results of feed intake, water intake, and feeding behavior are shown in Table 2 and 
Figure 1. As expected, across all treatments, DMI decreased (P < 0.01) before calving, and 
increased (P < 0.01) after parturition. Water intake tended to be decreased (P = 0.09) before 
calving, and increased dramatically (P < 0.01) after parturition. Pre- or postpartum DMI and 
water intake did not differ (P > 0.10) among treatments. There were quadratic dose effects (P < 
0.05) for prepartum meal size, meal length, meal frequency, and intermeal interval, reflecting 
decreased meal size, meal length, and intermeal interval, and increased meal frequency for cows 




 Milk Production and Body Condition 
As shown in Table 3 and Figure 1A, milk yield was not affected (P > 0.10) by treatments. 
There was a tendency for increased (P = 0.09, quadratic dose effect) milk fat percentage for cows 
receiving 30 and 60 g/d doses. Tendencies for increased percentages of milk protein (P = 0.08, 
linear dose effect) and lactose (P = 0.10, linear dose effect) were detected with increasing dose. 
Milk composition yields, SCM, and ECM (Figure 1B) were not affected (P > 0.10) by 
treatments. Body condition score (Figure 1C) decreased dramatically (P < 0.01) after calving, but 
was unaffected (P = 0.90) by treatments. 
 
 Plasma Metabolites  
As shown in Figure 3, significant day effects (P < 0.01) were observed for plasma 
glucose, BHBA, and NEFA, reflecting dramatic metabolic and endocrine changes during the 
transition period. There was a tendency for a quadratic dose effect (P = 0.06) for glucose, 
indicating that 30 and 60 g/d doses tended to decrease plasma glucose (69.6, 66.1, 67.0, and 68.7 
± 1.33 mg/dL for 0, 30, 60, and 90 g/d, respectively, throughout the experimental period), but no 
yeast product vs. control (P = 0.14), linear dose (P = 0.75), or treatment × day (P = 0.99) effects 
were detected. Interestingly, compared with control, yeast product increased plasma BHBA (P < 
0.01; 661.0, 882.0, 759.8, and 736.4 ± 41.3 µM for 0, 30, 60, and 90 g/d, respectively, 
throughout the experimental period). A significant quadratic dose effect (P < 0.01) was also 
detected. Although plasma NEFA was numerically increased by 30 and 60 g/d doses (P = 0.12, 
quadratic dose effect; 496.8, 565.7, 566.3, and 480.9 ± 48.7 µM for 0, 30, 60, and 90 g/d, 
respectively, throughout the experimental period), no yeast product vs. control (P = 0.47) or 




The transition period imposes tremendous stress on dairy cows and may result in 
inadequate nutrient and energy intake to support the onset of lactation. In this study, we 
attempted to evaluate if yeast product supplementatio  would modulate DMI, feeding behavior, 
and milk production of transition cows. We found that DM and water intake decreased before 
parturition and increased dramatically after calving, but were not affected by treatments either 
pre- or postpartum. Dann et al. (2000) reported that ye st culture increased DMI both pre- and 
postpartum in Jersey cows. Ramsing et al. (2009) recently reported that cows supplemented with 
yeast culture at 57 g/d throughout the transition period had an increased prepartum DMI by 1.5 
kg/d (P < 0.05), but postpartum DMI was not affected by trea ments. Other studies (Robinson, 
1997; Arambel and Kent, 1990; Swartz et al., 1994), however, reported no effects of yeast 
products on DMI.  
Changes in DMI ultimately result from changes in feeding behavior, quantified as 
number of meals consumed daily, the length of each meal, and the rate of eating that occurs 
during meals (Grant and Albright, 1995). Similar to the changes in DMI, we observed that most 
of the feeding behavior variables changed over timeeither pre- or postpartum. Consistent with 
the finding (Ramsing et al., 2009) that yeast culture increased (P = 0.02) the number of meals per 
day in prepartum cows, we observed increased meal frequency for cows received 30 and 60 g/d 
treatments. Ramsing et al. (2009) reported no difference in prepartum meal size, but here we 
detected a quadratic decrease in treated cows. The reasons for the discrepancies between the 2 
studies are not clear, but differences in feeding systems, meal criteria and calculation methods, 
and treatment products may have contributed. In our study, the increase in meals consumed per 
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day and decreased meal size may result in more consiste t prepartum intake patterns throughout 
the day. Although not measured directly, this modulated feeding behavior may be associated 
with improved rumen fermentation characteristics in response to yeast product supplementation 
(Marden et al., 2008; Piva et al., 1993; Yoon and Stern, 1996). Although no significant treatment 
effects were observed for postpartum feeding behavior, the numerically increased meals 
consumed per day (P = 0.19) and decreased meal size (P = 0.14) postpartum did seem to be 
similar to the patterns observed prepartum. If these changes would attenuate fluctuations of 
rumen pH, then yeast product would especially benefit these early-lactation cows by allowing 
them to better adapt to the sudden dietary shift. It should be noted that cows were housed in free-
stall prepartum and in tie-stall facilities postpartum, and the changes in feeding patterns from 
pre- to postpartum likely reflect differences in feeding behavior of cows in pen vs. tie-stall 
housing (Grant and Albright, 1995) in addition to a true stage of production effect. Regulation of 
feeding behavior and feed intake is complex, and is controlled by gut fill and chemostatic 
mechanisms. Factors such as feeding management, environment, health, and social interactions 
could affect feeding behavior and feed intake as well (Grant and Albright, 1995). 
Milk and milk component yields were not affected by yeast product supplementation, 
although there were tendencies for a quadratic increase in milk fat percentage and linear 
increases in milk protein and lactose percentages with increasing dose. Many studies (Arambel 
and Kent, 1990; Swartz et al., 1994; Robinson, 1997) reported no significant effects of yeast 
products on milk yield, and a few experiments reported positive milk responses (Nocek et al., 
2011; Ramsing et al., 2009). These data suggest that milk production responses to yeast product 
supplementation are rather variable; differences in parities, stages of lactation, product 
derivation, and environmental conditions could all contribute to the discrepancies. Given the 
 126
large variability in lactational performance in early lactation, more animals are needed to achieve 
adequate power to detect differences in milk respones. 
The dramatic changes in plasma metabolites throughout t e transition period are similar 
to the patterns observed in previous studies (Morey et al., 2011; Mullins et al., 2012). 
Supplementation of 30 and 60 g/d tended to decrease pl ma glucose. Although not significant, 
30 and 60 g/d treatments numerically increased plasma NEFA. Interestingly, yeast product 
increased plasma BHBA, and a significant quadratic dose effect was also detected, reflecting that 
the 30 g/d dose had the greatest effect in elevating BHBA. These changes point to an enhanced 
lipid mobilization in treated cows, which is consistent with the finding that 30 and 60 g/d doses 
tended to increase milk fat percentage. The reasons underlying this observation are not clear, but 
it is unlikely that yeast product had a direct effect on lipid metabolism. In fact, cows receiving 30 
g/d had a numerical decrease in postpartum DMI of 2.1 kg/d, and decreased feed intake in the 
transition period is a key risk factor for elevated BHBA and ketosis (Grummer, 1995).  
Together, these data suggest that yeast product supplementation did not affect milk 
production or DMI, but modulated feeding behavior and metabolism in transition dairy cows. 
Given the numerical differences in milk responses and DMI, together with changes of lipid 
metabolism markers, the 30 g/d dose did not benefit these cows; rather, it seems that 60 g/d dose 
provided the most benefits from the production and metabolic health standpoint. 
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Table 4-1 Ingredient and nutrient composition of diets. 
 
Item Prepartum Postpartum 
Ingredient, % of DM   
Corn silage 29.5 15.9 
WCGF1 21.3 34.3 
Alfalfa hay - 14.2 
Wheat straw 10.9 3.3 
Prairie hay 16.8 - 
Cottonseed - 5.0 
Ground corn 3.4 11.2 




Molasses 1.2 1.2 
Ca salts of long-chain fatty 
acids3 
- 0.8 
Micronutrient premix4 1.3 2.9 
   
Nutrient, % of DM   
DM, % as-fed 45.4 51.1 
CP 13.0 17.7 
Starch 21.1 20.2 
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ADF 24.4 16.9 
NDF 42.5 31.0 
NFC 33.8 41.1 
Ether extract 3.3 4.2 
Ash 6.0 8.3 
 
1 SweetBran, Cargill Inc., Blair, NE  
2 Soy Best, Grain States Soya, West Point, NE 
3 Megalac-R, Church & Dwight Co, Princeton, NJ
4 Prepartum premix consist of 53.0% vitamin E premix (44 IU/g), 11.6% selenium premix (600 
ppm Se), 10.5% trace mineral salt, 9.6% vitamin A premix (30 IU/g), 6.4% 4-Plex (Zinpro 
Corp., Eden Prairie, MN; contains 2.58% Zn, 1.48% Mn, 0.90% Cu, 0.18% Co, 8.21% Met, and 
3.80% Lys), 4.3% vitamin D premix (30 IU/g), 4.3% Rumensin 90, and 0.48% ethylenediamine 
dihydriodide premix (3.65% I).  
Postpartum premix consist of 47.5% limestone, 27.9% of sodium bicarbonate, 10.1% trace 
mineral salt, 6.4% magnesium oxide, 4.5% vitamin E premix (44 IU/g), 1.79% 4-Plex (Zinpro 
Corp., Eden Prairie, MN; contains 2.58% Zn, 1.48% Mn, 0.90% Cu, 0.18% Co, 8.21% Met, and 
3.80% Lys), 1.1% selenium premix (600 mg/kg Se), 0.56% vitamin A premix (30 IU/g), 0.01% 




Table 4-2 Feed intake and feeding behavior during the experimental period. Values are least squares means ± SEM, n = 9-10. 
 
 Treatment  P value 
Item 0g 30g 60g 90g SEM Yeast vs. Control Linear Quadratic 
Prepartum DMI, kg/d 12.1 11.9 12.6 12.1 0.51 0.86 0.77 0.76 
Prepartum water intake, L/d 49.0 48.3 49.0 51.3 2.38 0.84 0.48 0.53 
Meal frequency, d-1  10.1 11.4 11.2 10.0 0.45 0.12 0.80 0.01 
Intermeal interval, h 2.08 1.87 1.94 2.08 0.08 0.18 0.86 0.02 
Meal size, kg DM 1.23 1.06 1.16 1.24 0.06 0.27 0.68 0.04 
Meal length, min 20.6 17.7 17.3 21.1 1.58 0.31 0.87 0.04 
         
Postpartum DMI, kg/d 21.8 19.7 21.5 22.8 1.13 0.73 0.34 0.14 
Postpartum water intake, L/d 105.6 96.1 105.6 105.2 5.15 0.59 0.72 0.40 
Meal frequency, d-1 12.8 13.1 13.5 12.2 0.62 0.85 0.62 0.19 
Intermeal interval, h 1.50 1.50 1.42 1.60 0.08 0.90 0.53 0.29 
Meal size, kg DM 1.81 1.69 1.76 1.93 0.10 0.87 0.34 0.14 
Meal length, min 26.4 25.0 25.3 26.7 1.11 0.56 0.80 0.19 
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Table 4-3 Milk production and composition during the experimental period. Values are least squares means ± SEM, n = 9-10. 
 
 Treatment P value 
Item 0g 30g 60g 90g SEM Yeast vs. Control Linear Quadratic 
Milk yield, kg/d 45.3 42.6 47.8 46.7 2.53 0.90 0.39 0.72 
Milk fat, % 4.11 4.38 4.33 4.17 0.13 0.20 0.80 0.09 
Milk protein, % 2.99 2.89 3.04 3.12 0.07 0.76 0.08 0.17 
Milk lactose, % 4.77 4.74 4.84 4.85 0.05 0.45 0.10 0.67 
MUN, mg/dl 13.3 14.1 13.4 13.9 0.63 0.44 0.65 0.81 
Fat yield, kg/d 1.81 1.82 2.02 1.90 0.09 0.32 0.24 0.46 
Protein yield, kg/d 1.34 1.21 1.42 1.42 0.08 0.86 0.17 0.42 
Lactose yield, kg/d 2.16 2.03 2.32 2.26 0.13 0.78 0.30 0.79 
SCM1, kg/d 44.5 42.7 48.5 46.5 2.32 0.58 0.24 0.96 
ECM2, kg/d 48.5 46.5 52.4 50.5 2.45 0.63 0.26 0.99 
 
1 SCM = (12.3 × %fat) + (6.56 × % solids-non-fat) - (0.0752 × milk yield); (Tyrell and Reid, 1965) 
2 ECM = (0.327 × milk yield) + (12.86 × %fat) + (7.65 × %protein); (Dairy Records Management Systems, 2010)
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Figure 4-1 Dry matter intake (A), water intake (B), meal size (C), meal length (D), number 
of meals (E), and intermeal interval (F) during the experimental period. Yeast product was 
supplemented at 0, 30, 60, or 90 g/d to transition dairy cows from 21 d before expected calving 
to 42 d after calving. No treatment (P > 0.10) or treatment × day (P > 0.10) effects were 
observed for these variables. (A): Day effects (P < 0.01) both pre- and postpartum were 
observed; prepartum SEM = 0.86, postpartum SEM = 1.44. (B): A tendency for day effect 
prepartum (P = 0.09) and a day effect postpartum (P < 0.01) were observed; prepartum SEM = 
4.63, postpartum SEM = 7.02. (C): Day effects (P < 0.01) both pre- and postpartum were 
observed; prepartum SEM = 0.11, postpartum SEM = 0.17. (D): Day effects (P < 0.01) both pre- 
and postpartum were observed; prepartum SEM = 2.65,postpartum SEM = 1.81. (E): A 
tendency for day effect prepartum (P = 0.07) and a day effect postpartum (P = 0.03) were 
observed; prepartum SEM = 0.93, postpartum SEM = 1.00. (F): A day effect was observed 
prepartum (P < 0.01), but not postpartum (P = 0.18); prepartum SEM = 0.17, postpartum SEM = 
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Figure 4-2 Milk yield (A), ECM (B), and BCS (C)
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Figure 4-3 Concentrations of plasma metabolites during the experimental period.
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Chapter 5 - Yeast product supplementation modulated humoral and 
mucosal immunity and uterine inflammatory signals in transition 
dairy cows 
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The transition from late gestation to early lactation is characterized by substantial 
metabolic stress and suppressed immune function. The objective of this study was to assess the 
effects of supplementing a yeast product derived from Saccharomyces cerevisiae on immunity 
and uterine inflammation in transition cows. Forty multiparous Holstein cows were blocked by 
expected calving date and randomly assigned within block to 1 of 4 treatments (n = 10) from 21 
d before expected calving to 42 d postpartum. Rations were top-dressed with a yeast product 
(yeast culture plus enzymatically hydrolyzed yeast; Celmanax, Vi-COR, Mason City, IA) at the 
rate of 0, 30, 60, or 90 g/d throughout the experimnt. Colostrum samples were collected 
immediately after calving for analysis of immunoglobulin G (IgG) concentrations. Milk somatic 
cell count (SCC) was analyzed and converted to somatic cell linear score (SCS). Blood samples 
collected on -21, -7, 1, 4, 7, 14, 21, and 35 d relative to calving were analyzed for hematology 
and leukocyte differential and plasma haptoglobin; whole blood samples were incubated with E. 
coli (# 51813) to assess the ability of blood to kill bacteria. Cows were challenged on d -21, -7, 
and 14 with subcutaneous administration of ovalbumin with adjuvant; plasma samples collected 
on d -21, -14, and 21 were analyzed for anti-ovalbumin IgG content to assess humoral immune 
response. Fecal samples were collected on d 7 and 21 for analysis of IgA concentration. Uterine 
samples were collected on d 7 and 42 postpartum by cytobrush technique to determine neutrophil 
populations and relative abundance of transcripts involved in inflammation. Data were analyzed 
using mixed models with repeated measures over time. Concentrations of colostrum IgG were 
unaffected (P > 0.10) by treatments. A treatment × wk interaction (P < 0.01) was observed for 
SCS, reflecting a tendency for a quadratic dose effect on wk 1 (2.34, 2.85, 1.47, and 4.06 ± 0.59 
for 0, 30, 60, and 90 g/d, respectively; P = 0.08), and a quadratic dose effect on wk 5 (1.36, -0.15, 
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-1.07, and 0.35 ± 0.64 for 0, 30, 60, and 90 g/d, respectively; P = 0.02). Platelet count was 
increased by yeast product (P = 0.04). Plasma haptoglobin concentrations were not affected (P > 
0.10) by treatments. Percentages of E. coli killed by whole blood were not affected (P > 0.10) by 
treatments. Yeast product linearly increased (P < 0.01) plasma anti-ovalbumin IgG levels on d 21, 
suggesting that treatments enhanced humoral immunity. Yeast product quadratically increased 
fecal IgA concentrations (P = 0.03), suggesting that 30 and 60 g/d doses enhanced mucosal 
immunity. Uterine neutrophil populations were much greater in samples collected on d 7 
compared with those on d 42 (32.0 vs. 7.6 ± 3.7 % of cells, P < 0.01), reflecting neutrophil 
infiltration immediately after calving, but no treatment effect (P = 0.53) was detected. There 
were significant day effects (P ≤ 0.01) for IL-6, IL-8, neutrophil myeloperoxidase, and 
neutrophil elastase mRNA in uterine sample, reflecting greater abundance of these transcripts 
collected on d 7 compared with d 42. Interestingly, there was a quadratic dose effect (P = 0.02) 
for IL-6, indicating that 30 and 60 g/d decreased uterine IL-6 mRNA. The mRNA abundance of 
neutrophil myeloperoxidase and elastase was increased (P < 0.05) by yeast product. Yeast 
product supplementation enhanced humoral and mucosal immunity, and modulated uterine 
inflammatory signals and mammary gland health in tra sition dairy cows.  
 





 Introduction  
The transition from late gestation to early lactation is characterized by substantial 
metabolic stress and suppressed immune function, which may contribute to the markedly 
elevated incidence of health disorders in early-lactation dairy cows (Goff and Horst, 1997). 
Therefore, it is critical to develop effective nutritional strategies that could modulate the 
immunity of these animals. Yeast products derived from Saccharomyces cerevisiae have been 
shown to improve feed intake and milk yield in transition cows ((Dann et al., 2000; Ramsing et 
al., 2009). Recent findings suggest yeast products may also enhance immune function. Kim et al. 
(2011) reported that neonatal calves fed hydrolyzed yeast showed enhanced acute phase 
response, antibody production, and health scores whn c allenged with live vaccines, compared 
with controls. Such responses could be attributed to improved energy status via effects on 
digestive function, or on activation of the immune system through cell sensing of yeast 
components in the gut and subsequent cross-talk between immune cells.  
One overlooked aspect of the response to yeast is the potential to influence mucosal 
immunity. Mucosal surfaces of the intestinal and reproductive tracts are among the most 
important routes of entry of microbial pathogens into the host. Epithelial cells that line mucosal 
surfaces are important mechanical barriers to prevent most microbes found in the environment, 
including commensal microbes, from entering epithelal cells (Kagnoff and Eckmann, 1997). A 
recent study (Zanello et al., 2011) reported that ye st modulated the expression of genes involved 
in inflammation and recruitment and activation of immune cells in porcine intestinal epithelial 
cells. Specifically, yeast decreased both the transcript and protein abundance of pro-
inflammatory genes, including interlukine-6 (IL-6) and IL-8, in response to E. coli exposure. 
 146
Together, interest in yeast products for dairy cows ha  expanded beyond a focus on 
improving production. There are intriguing data suggesting that yeast products can improve 
immune function, particularly during physiological challenges. The objectives of this study were 
to assess whether yeast product alters: 1) immunity, assessed as milk SCS, colostrum 
immunoglobulin G (IgG) concentrations, hematology and leukocyte differential, the ability of 
blood immune components to kill E. coli, IgG antibody production after vaccination, and IgA
secretion from the gut mucosa; 2) uterine inflammation, as determined by neutrophil populations 
and transcript abundance of inflammatory genes in uterine tissues. 
 
 Materials and Methods 
The Kansas State University Institutional Animal Care nd Use Committee approved all 
the experimental procedures.  
 
 Design and Treatments 
Forty multiparous Holstein transition cows from theKansas State University Dairy Cattle 
Teaching and Research Facility were used in a randomized complete block design. Cows were 
blocked by expected calving date (10 blocks), and romly assigned within block to 1 of 4 
treatments 21 d before their expected calving date. Cows remained on their respective treatments 
through 42 d postpartum. Cows received a yeast product (yeast culture plus enzymatically 
hydrolyzed yeast; Celmanax, Vi-COR, Mason City, IA)at a rate of 0, 30, 60, or 90 g/d. Yeast 
product was administered daily to each cow in the treatment groups by top-dressing and 
manually mixing the premix into the upper part of each TMR. Diets were formulated to meet or 
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exceed NRC (2001) requirements; ingredient and nutrient composition of the diet were reported 
in a companion paper (Yuan et al., 2014).  
 
 Management of Cows and Data Collection 
Dry cows were moved into the maternity barn approximately 1 wk before entering the 
study. Cows were allowed ad libitum access to the designated treatment rations by an electronic 
gating system (Roughage Intake System, Insentec B.V., Marknesse, The Netherlands). After 
parturition, cows were moved into a tie-stall facility where they remained through 42 d 
postpartum. Dry cows were fed ad libitum twice daily (1100 and 1800 h), and lactating cows 
were fed twice daily (1200 and 1900 h). Lactating cows were milked 3 times daily in a milking 
parlor. Feed intake, feeding behavior, and milk yields were recorded as described in Yuan et al. 
(2014). Milk samples were collected 3 consecutive days each week, and were analyzed for 
somatic cells (SCC 500, Bentley Instruments; Heart of America DHIA, Manhattan, KS). 
Colostrum samples were collected immediately after calving and were kept frozen at -20°C until 
analysis of IgG concentration (Cornell Diagnostic Lab, Ithaca, NY). 
Cows were challenged (subcutaneous injection) with 1 mg of chicken egg ovalbumin 
(Sigma-Aldrich, St. Louis, MO) diluted in vaccine adjuvant (VET-SAP, Desert King 
International, San Diego, CA; 0.5 mg of adjuvant dissolved in 1 mL of saline) on d -21, -7, and 
14. Blood samples were collected on d -21, -14, -7, 1, 4, 7, 21, and 35 relative to calving from 
the coccygeal vessels 1 h prior to feeding. Approximately 20 mL of blood was collected into 4 
tubes: one 7-mL tube containing potassium EDTA, one 3-mL tube containing potassium EDTA, 
one 5-mL tube containing heparin, and another 7-mL tube containing potassium oxalate with 
sodium fluoride as a glycolytic inhibitor (Vacutainer, Becton Dickinson, Franklin Lakes, NJ, 
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USA). Fecal samples were collected on d 7 and 21, and were frozen at -20°C until analysis of 
IgA concentration. 
Endometrial samples were collected approximately on d 7 (7.2 ± 1.0 d across treatments; 
7.2, 6.8, 7.3, and 7.3 ± 0.35 d for 0, 30, 60, and 90 g/d, respectively; P = 0.68) and 42 (40.9 ± 1.6 
d across treatments; 40.9, 41.4, 40.2, and 41.0 ± 049 d for 0, 30, 60, and 90 g/d, respectively; P 
= 0.40) postpartum by cytobrush. Prior to the procedur , the vulva was cleaned with paper 
towels. Then, a cytological sample of the endometrium from the dorsal aspect of the uterine body 
was collected using a cytobrush (Cytobrush Plus; CooperSurgical Inc., Trumball, CT) as 
reported before (Mendonça et al., 2013). Briefly, the cytobrush was placed into the stainless steel 
tube of an insemination pipette. The device was placed into a sanitary plastic chemise (Agtech, 
Inc., Manhattan, KS). Endometrial sampling was performed by inserting the instrument through 
the vagina into the uterine body. Once the device was pushed forward into the uterine body, the 
sanitary chemise was punctured and the plastic sheath r tracted to expose the cytobrush. Once 
the brush had been rolled onto the uterine wall, it was pulled back into the plastic sheath and 
removed from the vagina. Slides for cytological examination were prepared by rolling the 
cytobrush on a clean glass microscope slide.  
Cows were monitored daily for health status. Ketosis was recorded when urine 
acetoacetate exceeded 80 mg/dL on any day or 40 mg/dL for 2 consecutive days (Ketostix; 
Bayer Corp. Diagnostics Division, Elkhart, IN). Other disorders or diseases were diagnosed 
according to the guidelines by Kelton et al. (1998).  
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 Sample Analysis 
Blood samples from the 7 mL potassium EDTA tube and the 7 mL tube containing 
potassium oxalate with sodium fluoride were centrifuged at 2,000 × g for 10 min immediately 
after sample collection, and plasma was harvested and frozen at -20°C until subsequent analysis 
of glucose (reported in Yuan et al., 2014), BHBA (reported in Yuan et al., 2014), NEFA 
(reported in Yuan et al., 2014), and haptoglobin cocentrations. Haptoglobin was analyzed by a 
colorimetric method based on peroxidase activity (Cooke and Arthington, 2013). The standard 
curve was prepared using plasma samples from another res arch project (Yuan et al., 2013) with 
known haptoglobin concentrations, which were analyzed by ELISA (ELISA kit #2410-7; Life 
Diagnostics, West Chester, PA).  Absorbance was read on a spectrophotometer (Powerwave XS, 
Biotek Instruments, Winooski, VT, USA) and calculations were conducted using Gen5 software 
(Biotek Instruments). 
Blood collected from the 3-mL potassium EDTA tube was analyzed for hematology 
using a ProCyte hematology analyzer (IDEXX Laboratories, Westbrook, ME). Whole blood 
collected from the 5-mL tube containing heparin was used to test its bactericidal capacities 
against live cultures of environmental E. coli (ATCC# 51813) according to methods previously 
described (Ballou, 2012). Briefly, an overnight broth culture of the E. coli was diluted in 
nonpyrogenic 1× PBS to an approximate concentration of 25 cfu/µL and kept in an ice bath. 
Whole blood was diluted 1:1 with RPMI-1640 to a final volume of 200 µL. All tubes were 
placed in an ice bath for 5 min. Then, 50 µL of the working E. coli culture was added to each 
tube of diluted whole blood, vortexed, and incubated in a water bath at 37.5°C for 5 min. 
Following incubation, the cultures were vortexed, 50 µL of each culture was pipetted and spread 
plated onto tryptic soy agar plates in duplicate, and the plates were incubated overnight at 36.5°C 
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before determination of the number of cfu. Data are expressed as the percentage of reduction in 
cfu for blood samples vs. controls.  
Plasma samples collected on d -21, -14, and 21 wereanalyzed for anti-ovalbumin IgG 
using an ELISA modified from a method described by Mallard et al. (1997). All cows were 
analyzed for d -21 and -14 samples; only cows that received 3 doses of chicken egg ovalbumin 
injection (on d -21, -7, and 14) were retained for the analysis of d 21 samples. Briefly, 96-well 
plates (Corning Costar high binding 96 well plate, Thermo Fisher Scientific Inc.) were coated 
with 100 µL of coating solution: 16.8 chicken egg ovalbumin (Sigma-Aldrich) diluted in 12 mL 
0.05 M carbonate-bicarbonate buffer (pH 9.4). Plates w re incubated overnight at room 
temperature and washed 5 times with wash buffer (PBS and 0.05% Tween solution, pH 7.4). 
Plates were then blocked with 300 µL of blocking buffer (4% bovine serum albumin, 5% sucrose 
in PBS, 0.2 µm filtered) and incubated overnight at 4°C. Plates w re washed 5 times, and blank 
(wash buffer), diluted plasma (l:200), and pooled samples from d -21 (negative control, l:200) 
and 21 (positive control, l:200) were added in duplicates. Plates were incubated for 1 h at room 
temperature and washed 5 times. Subsequently, anti-bovine IgG (Anti-Bovine IgG -peroxidase 
antibody produced in rabbit, Sigma-Aldrich) was diluted with 10 mM Tris buffer solution at 
1:30,000, added to the plates and incubated for 1 h at room temperature. Plates were then washed 
5 times, and 100 µL of 3,3’,5,5’-tetramethylbenzidine substrate soluti n (TMB Solution; Thermo 
Fisher Scientific Inc.) was added to each well and llowed to incubate for 3 min at room temperature, 
followed by the addition of 100 µL of stop solution (0.18 M sulfuric acid). Optical density (OD, 
blank-adjusted) was measured at 450 nm using a plate re der (PowerWaveXS, BioTek, Winooski, 
VT). The final OD was corrected across different plates to achieve a positive control optical density 
= 0.5. For each sample, final OD = 0.5 × original OD ÷ positive control OD of that plate. 
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For fecal IgA analysis, the frozen fecal samples were thawed and placed immediately in 
ultra purified water at a concentration of 10% w/v by weighing 1 g of feces and adding 9 mL of 
water. Samples were then vortexed vigorously and incubated overnight before being spun at 
2,000 × g for 15 min. The supernatants were collected and analyzed for IgA by ELISA according 
to the manufacturer’s instructions (Bovine IgA ELISA Quantitation Set, Bethyl Laboratories, 
Montgomery, TX). 
For morphological assessment of uterine samples, slides were stained with modified 
Wright Giemsa stain (Protocol-Hema3, Bio-chemical Sciences, Swedesboro, NJ). Each slide was 
examined at 400 × magnification to perform a differential cell count of at least 200 cells 
(neutrophils + endometrial cells) by a single observer. The result of this examination was 
reported as neutrophils as a percentage of all cells.  
Total RNA was extracted from uterine tissue using a commercial kit (RNeasy Lipid 
Tissue Mini Kit; Qiagen Inc., Valencia, CA) according to the manufacturer’s instructions, and 
spectroscopy was used to quantify RNA (Nanodrop-1000, Nanodrop Technologies Inc., 
Wilmington, DE). Quality of RNA (integrity number = 6.78 ± 1.09 for a random subset of 16 
samples was verified with an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). 
Then, RNA was reverse-transcribed to cDNA and mRNA abundance of IL-6, IL-8, neutrophil 
myeloperoxidase, and neutrophil elastase was determined by qPCR as described (Yuan et al., 
2013). Briefly, 2 mg of total RNA was used as the template for the reverse transcriptase reaction 
using random primers (High-Capacity cDNA RT Kit; Life Technologies, Carlsbad, CA). 
Quantitative real-time PCR (RT-PCR) was performed in uplicate on 96-well plates with 5% of 
the cDNA product in the presence of 200 nM gene-specific forward and reverse primers with 
real-time SYBR green fluorescent detection using SYBR Green Premix reagent (7500 Fast Real-
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Time PCR System, Life Technologies). Primers were designed 
(www.ncbi.nlm.nih.gov/tools/primer-blast/) using GenBank sequences (Table 1). Data were 
recorded and analyzed with Sequence Detector software (Life Technologies). All sample values 
were normalized against the geometric mean of 3 control genes, ribosomal protein subunit 9 
(RPS9), RPS15, and β-actin, and relative transcript abundance was quantified by using the 2−∆Ct 
method.  
 
 Data and Statistical Analysis 
One cow in the 0 g/d group was removed from the study on d 30 postpartum due to 
difficulty standing up in the tie-stall. Data obtained from this cow prior to removal were included 
in all analyses. Data were analyzed using mixed models with repeated measures over time. 
Models included the fixed effects of treatment, time, and their interaction, and the random effect 
of cow. Contrast statements were used to assess the overall effect of yeast product (control vs. all 
yeast product treatments), as well as the linear and quadratic effects of dose. If treatment by time 
effects were significant, slices were used to assess effects on specific days. Values were deemed 
outliers and omitted from analysis when Studentized residuals were greater than > |3.0|. After 
initial outlier removal, the model was repeated andStudentized residuals greater than > |3.5| 
were deemed outliers. When necessary, data (including plasma haptoglobin, fecal IgA, uterine 
transcript abundance of IL-6, IL-8, neutrophil myeloperoxidase, and neutrophil elastase) were 
log-transformed prior to analysis to achieve normal residual distributions, and reported means 
and standard errors are back-transformed. Milk SCC was converted to SCS (Shook et al., 1993). 
Regression analyses were used to explore relationships between different measures. For each 
regression analysis, the distribution of Cook’s D stati tic was visually checked and outliers were 
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There were no differences among groups in prepartum dietary treatment length (18.1, 
18.8, 17.8, and 17.2 ± 1.32 d for 0, 30, 60, and 90 g/d, respectively; P = 0.86). Actual calving 
dates ranged from 13 d before expected calving to 5 d after expected calving. Results for feed 
intake and milk production were reported in Yuan et al. (2014), and they were not affected (P > 
0.10) by yeast product treatments. 
 
 Milk Constituents 
As shown in Figure 1, there was a treatment × wk interaction (P < 0.01) for milk SCS, 
reflecting a tendency for a quadratic dose effect on wk 1 (2.34, 2.85, 1.47, and 4.06 ± 0.59 for 0, 
30, 60, and 90 g/d, respectively; P = 0.08), and a quadratic dose effect on wk 5 (1.36, -0.15, -
1.07, and 0.35 ± 0.64 for 0, 30, 60, and 90 g/d, respectively; P = 0.02). As shown in Figure 2, 
concentrations of IgG in colostrum collected immediately after calving were not affected by 
treatments (P = 0.96). 
 
 Hematology and Leukocyte Differential 
Results of hematology and leukocyte differential analysis are shown in Table 2. There 
were no treatment effects (P > 0.10) for erythrocyte count, hemoglobin, or leukocyte count. 
Hematocrit was linearly decreased (P = 0.04) by treatment. Platelet count was increased by yeast 
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product compared with control (P = 0.04). Concentrations and fractions of lymphocytes, 
monocytes, eosinophils, and basophils were not affected (P > 0.10) by treatments; neutrophil 
concentrations, but not fraction, were decreased (P < 0.05) by yeast supplementation. As shown 
in Table 3, there were day effects (P < 0.01) for erythrocyte count, hemoglobin, hematocri , and 
leukocyte count. Specifically, hemoglobin, hematocri , and erythrocyte count were decreased on 
d 21 and 35 compared with other dates; leukocyte count was increased on d 1 after calving; 
platelet count was decreased at the week around parturition compared with d -21, and increased 
on d 21 and 35. Both concentrations and fraction of eutrophils were elevated at calving; those 
of lymphocytes were greater at d -21 compared with other dates, monocytes were increased 
postpartum compared with prepartum, and eosinophils were decreased postpartum compared 
with prepartum. 
 
 Plasma Haptoglobin 
As shown in Figure 3, haptoglobin was not altered by yeast product (P = 0.15, yeast 
product vs. control). No linear dose (P = 0.28), quadratic dose (P = 0.35) or treatment × day (P = 
0.35) effects were detected. 
 
 Whole Blood Killing of Bacteria 
As shown in Figure 4, the proportion of bacteria killed by heparinized whole blood was 
not affected by treatments (P = 0.28). Although the values decreased numerically at the time 
around parturition compared with 3 wk before or after calving, this change did not reach a 
significant day effect (P = 0.19). No treatment × day effect (P = 0.99) was detected. 
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 Antibody Production 
As shown in Figure 5, anti-ovalbumin IgG levels increased dramatically (P < 0.01) after 
3 ovalbumin challenges (d 21) compared with pre-immunization (d -21).  Throughout the 
experimental period, there was a tendency for increased anti-ovalbumin IgG in cows receiving 
yeast product (P = 0.06; linear dose effect). A treatment × day effect (P < 0.01) was also 
detected, reflecting that yeast product linearly increased (P < 0.01) anti-ovalbumin IgG on d 21. 
As shown in Figure 6, fecal IgA concentrations were not different (P = 0.61) between d 7 and 21, 
but yeast product quadratically increased (P = 0.03) fecal IgA concentrations.  
 
 Uterine Inflammation 
As shown in Figure 7, uterine neutrophil populations were much greater in samples 
collected on d 7 compared with d 42 (32.0 vs. 7.6 ± 3.7 % of cells, P < 0.01). There were no 
treatment (P = 0.53) or treatment × day effects (P = 0.75). No correlation (P = 0.64, R2 = 0.01) 
between d 7 and 42 uterine neutrophil populations wa detected. No treatment effect (P = 0.39) 
was detected for incidence of subclinical endometritis, as defined by the presence of >10% 
neutrophil in uterine samples collected at d 42 (Kasim nickam et al., 2004). As shown in Table 1, 
the median Ct values of RT-PCR for IL-6, IL-8, neutrophil myeloperoxidase, and neutrophil 
elastase were 26.6, 20.0, 36.3, and 34.0 ± 3.5, respectively, indicating that the abundance of 
neutrophil myeloperoxidase and elastase is much less compared with IL-6 and IL-8. As shown in 
Figure 8, there were significant (P ≤ 0.01) day effects for IL-6, IL-8, neutrophil 
myeloperoxidase, and neutrophil elastase, reflecting greater abundance of these transcripts in 
uterine tissues collected on d 7 compared with d 42. Specifically, compared with d 42, the 
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abundance of uterine IL-6 and IL-8 was over 25-fold greater on d 7, and that of neutrophil 
myeloperoxidase and elastase was over 2-fold greater. Interestingly, there was a qu dratic dose 
effect (P = 0.02) for IL-6, indicating that 30 and 60 g/d doses decreased uterine IL-6 mRNA 
abundance. No treatment effects (P > 0.10) were detected for IL-8. The abundance of neutrophil 
myeloperoxidase (P = 0.05, linear dose effect) and elastase (P = 0.03, linear dose effect) was 
increased by yeast product. The abundance of neutrophil elastase was positively correlated with 
neutrophil populations on d 42  (P = 0.02, R2 = 0.29), but not on d 7 (P = 0.65, R2 = 0.08). 
Abundance of other transcripts was not correlated with neutrophil populations (P > 0.10). To 
explore the possible link between systemic and uterine tissue inflammation, we examined the 
correlation between d 7 plasma haptoglobin concentrations and d 7 uterine neutrophil 
populations, and a significant positive association was detected (P < 0.01, R2 = 0.23, Figure 9).  
 
 Health Disorders 
Incidence of health disorders was not affected by treatments (P > 0.10, Table 4). To 
determine if retained placenta was linked to uterine inflammation, we compared neutrophil 
populations in cows with and without retained placenta. As shown in Figure 10, cows with 
retained placenta had greater (P < 0.01) neutrophil populations. In addition, cows that developed 
retained placenta also had much greater concentrations of plasma haptoglobin (4781 vs. 739 ± 





Increasing evidence suggests that yeast product may i prove immune function during 
physiological challenges. We found a tendency for a qu dratic dose effect for SCS on wk 1 and a 
quadratic dose effect on wk 5 of lactation, reflecting decreased SCS by 30 and 60 g/d doses. 
These results suggest that yeast product modulated mammary gland health in early lactation 
cows. Similarly, Nocek et al. (2011) reported that supplementation of yeast product throughout 
the first 14 wk of lactation decreased SCC and cases of clinical mastitis. Interestingly, the 
finding that 90 g/d increased SCS on the first week of lactation suggests that this dose might 
have exceed the optimal level of supplementation, smehow promoting an adverse inflammatory 
response in the mammary gland.  
Colostrum is a rich source of immune components. As the major immunoglobulin class 
present in bovine colostrum, IgG plays a key role in passive immunization of the offspring and 
protection of the mammary gland itself (Stelwagen et al., 2009). In this study, colostrum IgG 
concentrations were not affected by treatments, indicating that yeast product did not affect the 
quality of main colostrum immune component. However, b cause colostrum volume was not 
recorded, we were unable to assess treatment effects on the amounts of IgG produced. 
Both concentrations and relative proportions of neutrophils in blood were elevated at 
calving, which is consistent with the fact that cows typically experience a surge of blood 
neutrophils at parturition (Burton and Erskine, 2003). Total leukocyte count was also increased 
on d 1 after calving. Despite increased immune cell numbers, their function is often impaired, 
resulting in immune deficiency in the transition period (Burton and Erskine, 2003). Interestingly, 
yeast product supplementation decreased concentratio s of neutrophils, indicating a modulatory 
effect on immune cells. Although there were no treatment effects, hemoglobin, hematocrit, and 
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erythrocyte count were decreased on d 21 and 35 compared with other dates; it is possible that 
these changes resulted from increased plasma volume associated with increased milk output as 
lactation proceeds (Burton et al., 1992). Platelet count was decreased in the week around 
parturition compared with d -21, and increased on d 21 and 35. Because of their abundance and 
their ability to rapidly release cytokines and other immune mediators, platelets play a central role 
in modulating immune function (Jenne et al., 2013; Li et al., 2012). Recent evidence suggests 
that platelets can directly modulate neutrophil function and clear pathogens (Jenne et al., 2013). 
The temporal of changes in platelet counts in our study seem to be consistent with the changes of 
neutrophil function in the transition period (Kehrli et al., 1989). Given the importance of 
platelets in immune modulation, it is possible that pl telets can be used as an indicator of 
immune function in transition cows. We also found that yeast product increased platelet count, 
which is consistent with the finding that hydrolyzed yeast supplementation dramatically 
increased platelet count in neonatal calves challenged with vaccine (Kim et al., 2011). Whether 
this increase reflects an enhanced immune function is not clear.  
As an acute phase protein released primarily by the liver in inflammation, haptoglobin 
has consistently been shown to be increased at the time around parturition (Saremi et al., 2012; 
Mullins et al., 2012; Yuan et al., 2013). Recent work (Sabedra, 2012) using 161 transition cows 
found that serum haptoglobin was elevated around calving even in cows that were apparently 
healthy; cows experienced diseases had significantly greater concentrations compared with 
healthy animals. In this study, plasma haptoglobin means for yeast product treatments were 
~50% of control means; however, this was not significant (P = 0.15), reflecting large variations 
in haptoglobin concentrations among cows. Although previous in vitro studies (Jensen et al., 
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2008; Zanello et al., 2011) demonstrated that yeast and yeast culture possess anti-inflammatory 
effects, further in vivo studies are needed to verify these findings.  
Several studies (Ballou, 2012; Ballou et al., 2009) have used whole blood killing of 
bacteria to assess immune function in cattle. It is known that transition cows experience a 
dramatic decrease in immune cell function (Kehrli et al., 1989), and this change was reflected in 
significant decrease in whole blood anti-microbial c pacity at calving (Ballou et al., 2009). In 
this study, we observed a numerical decrease in blood killing ability at the time around 
parturition compared with 3 wk before or after calving, but this did not reach a significant day 
effect. It is possible that the assay we used is not sensitive enough to detect the previously-
reported changes in immune function, as the killing capacity can be largely affected by types of 
bacteria used, dilution of blood, incubation time, and many other assay conditions (Liebl and 
Martin, 2009; Millet et al., 2007). Under our experimental conditions, the percentage of bacteria 
killed by whole blood was not affected by yeast product treatments. 
To assess humoral immune response, we injected chicken egg ovalbumin, an antigen that 
these animals naïve to, to cows on d -21, -7 and 14, and measured plasma anti-ovalbumin IgG 
levels on d -21 (pre-immunization), -14, and 21. By using a similar vaccination approach, Burton 
et al. (1993) reported that Cr supplementation enhanced humoral immune response. Mallard et 
al. (1997) partitioned transition cows into 3 groups based on antibody response (i.e. high, low, 
and no responders) to ovalbumin challenge, and found that cows with the highest antibody 
response also tended (P ≤ 0.10) to have the highest response to E. coli challenge at parturition 
and had the lowest incidence of diseases, particularly mastitis. As expected, after 3 ovalbumin 
challenges, anti-ovalbumin IgG increased dramatically. Yeast product also linearly increased (P 
< 0.01) levels of anti-ovalbumin IgG on d 21, indicat ng that yeast product supplementation 
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enhanced humoral immunity. The positive effects of yeast products on humoral immunity have 
been observed across different species. Franklin et al. (2005) reported that supplementation of 
yeast cell wall components, mannanoligosaccharides, to cows during the last 3 wk of the dry 
period enhanced their humoral immune response to rotavi us and tended to enhance the 
subsequent transfer of rotavirus antibodies to calves. Muthusamy et al. (2011) reported that 
feeding hydrolyzed yeast and yeast cell wall components increased blood antibody level against 
Newcastle disease virus vaccination in broilers. Another key constituent of yeast cell wall, β-
glucan, has also been shown to enhance the defense against infections in rodent models 
(Samuelsen et al., 2014). 
Mucosal immune responses are the first line of defense because most pathogenic agents 
enter the host via mucosal surfaces, and IgA secreted by gut plays crucial roles in this mucosal 
defense by entrapping microorganisms and preventing the adherence of pathogens to mucosal 
surface (Neutra and Kozlowski, 2006). Recent research lso indicates that secretions of IgA are 
critical in the homeostasis of gut microbiota (Suzuki et al., 2004). Several studies have used fecal 
IgA concentration as an indicator of mucosal immunity. Gurzell et al. (2013) observed that fish 
oil supplementation in mice improved mucosal immune function by increasing secretory fecal 
IgA, and the numbers and function of B cells in gut-associated lymphoid tissues. Scholtens et al. 
(2008) reported that prebiotic oligosaccharide supplementation in milk formula increased fecal 
IgA concentrations in infants; together with the altered composition of intestinal microbiota in 
response to treatment, the authors concluded that the increased IgA suggests a positive effect of 
prebiotic on mucosal immunity. Viljanen et al. (2005) found probiotic supplementation increased 
fecal IgA and decreased tumor necrosis factor-α (TNFα) concentrations in infants with food 
allergic atopic eczema, and proposed that this increased IgA indicates an attempt of the host to 
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protect the gut from allergic food antigens, whereas decreased TNFα suggests that probiotics 
decreased inflammation in the gut. In this study, yeast product quadratically increased fecal IgA 
concentrations, suggesting that 30 and 60 g/d doses enhanced mucosal immunity. Previous 
research has demonstrated several possible mechanisms of the immunostimulatory effects of 
yeast product components. For example, mannanoligosaccharides can act as anti-adhesive agents 
and prevent colonization of pathogens in the intestinal tract by providing alternative adhesion 
sites to intestinal bacteria (Ganner and Schatzmayr, 2012). Furthermore, yeast components have 
been reported to have structural benefits to the intestine by increasing villus height and number 
of goblet cells (Muthusamy et al., 2011; Solis De Los Santos et al., 2007), which are responsible 
for the secretion of intestinal mucus. Increased mucus would in turn help to lubricate intestinal 
surfaces, trap and neutralize bacteria, and protect epithelial cells (Johansson et al., 2013), all of 
which could contribute to intestinal immune health. 
After the transition period, one major hurdle for the dairy cow is the return to estrus and 
breeding. We proposed to explore the impact of yeast product on neutrophil populations and 
expression of inflammatory mediators in the uterus at 2 key time points: d 7 and 42 postpartum. 
It is common that at least some bacteria are present in the uterus in the first week after calving 
(LeBlanc et al., 2011), and that the presence of neutrophils in the uterus is needed to clear 
pathogens and facilitate the involution of reproductive tissues (Challis et al., 2009). By day 42 
postpartum, cows that mounted a sufficient immune response will have cleared the bacteria, and 
neutrophil populations and expression of inflammatory mediators should be minimal, but other 
cows will still be fighting persistent infections (LeBlanc et al., 2011). It is widely believed that 
such persistent infections greatly impair fertility. Therefore, these measures investigated a 
potential link between dietary yeast product and reproductive success. We did not find treatment 
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effects for uterine neutrophil populations, but across treatments, there were much greater 
numbers of neutrophils in samples collected on d 7 compared with d 42. Most studies (LeBlanc, 
2008; Deguillaume et al., 2012; Dubuc et al., 2010) have examined cytobrush samples in cows > 
35 postpartum; in this study, we did not detect a correlation between d 7 and 42 neutrophil 
populations, indicating that greater presence of neutrophils in the uterus on d 7 does not predict 
incidence of subclinical endometritis on d 42. Neutrophil infiltration immediately after calving is 
not necessary detrimental but rather is a normal physiological response needed to clear 
pathogens and repair reproductive tissues (Challis et al., 2009).  
We also evaluated transcript abundance of IL-6 and IL-8 as indicators of uterine 
inflammation. As important pro-inflammatory cytokines, IL-6 and IL-8 have been shown to be 
expressed in the uterine tissues of postpartum cows, and the abundance of these transcripts was 
highly correlated with subclinical endometritis (Ghasemi et al., 2012). In order to directly assess 
neutrophil inflammatory status, we also evaluated the mRNA abundance of 2 neutrophil-derived 
enzymes, neutrophil myeloperoxidase and neutrophil elastase. Myeloperoxidase is a lysosomal 
protein stored in nuetrophil azurophilic granules and plays a key role in the microbicidal activity 
of neutrophils (Klebanoff, 2005). As a serine proteas , neutrophil elastase is responsible for 
degradation of proteins during phagocytosis, as well as degradation of connective tissue during 
an inflammatory process (Helmig et al., 2002). Interestingly, we found that the abundance of IL-
6 and IL-8 was over 25-fold greater in samples collected on d 7 compared with d 42, indicating 
much greater inflammation in uterus immediately after calving. Similarly, the abundance of 
neutrophil myeloperoxidase and neutrophil elastase was over 2-fold greater on d 7 compared 
with d 42, consistent with the finding that neutrophil populations in uterine samples were greater 
on d 7 compared with d 42. Osmers et al. (1995) report d a significant increase in IL-8 
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concentrations in human uterine tissue at the time of parturition, and this increase was strongly 
correlated with concentrations of multiple neutrophil collagenases, enzymes involved in the 
breakdown of extracellular matrix. Thomson et al. (1999) demonstrated that not only neutrophil 
populations, but also the expression of neutrophil adhesion molecules, such as E-selectin, were 
increased in endothelium during labor. These data suggest that inflammatory mediators play a 
crucial role in neutrophil influx to facilitate partu ition.  
In the present study, the abundance of neutrophil myeloperoxidase and elastase was 
much less compared with IL-6 and IL-8. This is not surprising because IL-6 and IL-8 are 
expressed by multiple cell types, whereas myeloperoxidase and elastase are only present in 
neutrophils, the relative quantities of which are very small. Despite the low abundance of 
myeloperoxidase and elastase, they nevertheless can serve as sensitive indicators of uterine 
inflammatory status. Indeed, abundance of neutrophil elastase was the only transcript 
investigated which was positively associated with uterine neutrophil infiltration on d 42, 
suggesting that uterine neutrophil elastase abundance could serve as a diagnostic marker for 
subclinical endometritis. We also observed some treatment effects on the abund nce of these 
transcripts. Supplementation of yeast product at 30 and 60 g/d, but not 90 g/d, decreased uterine 
IL-6 mRNA abundance. The abundance of neutrophil myeloperoxidase and elastase was linearly 
increased by treatments. Although several lines of evidence (Kim et al., 2011; Jensen et al., 
2008; Zanello et al., 2011) indicate yeast or yeast culture may modulate inflammation, no 
previous research evaluated the effects of dietary yeast products on the inflammatory profiles of 
reproductive tissues. Although yeast product exerted inconsistent effects on different uterine 
inflammatory signals and the implications are unclear, our findings nevertheless indicate that 
 164
certain nutritional strategies are effective in modulating inflammation, and perhaps reproductive 
function. 
To explore the relationships among reproductive disor ers, uterine inflammation, and 
plasma markers, we examined the correlations among the incidence of retained placenta, uterine 
neutrophil populations, and plasma haptoglobin and BHBA. We found a positive link between d 
7 plasma haptoglobin and d 7 uterine neutrophil populations, and that cows with retained 
placenta had greater neutrophil infiltration on both d 7 and 42. In addition, cows that experienced 
retained placenta had much greater concentrations of plasma haptoglobin and BHBA on d 7. In 
this study, all of the cows that had retained placenta (a total of 6) also developed metritis, 
consistent with previous reports of a direct link between these 2 conditions (LeBlanc, 2008). 
Previous studies (Skinner et al., 1991; Huzzey et al., 2009) have demonstrated that blood 
haptoglobin is a sensitive marker of uterine diseases. These results indicate that inflammation in 
local tissues (i.e. the reproductive tract) may lead to systemic inflammation and possibly 
impaired health. Consistent with our findings, Galvão et al. (2010) reported that cows that 
developed metritis had much greater concentrations of plasma haptoglobin and BHBA. Hammon 
et al. (2006) found that cows that developed metritis or subclinical endometritis had greater 
plasma BHBA and impaired blood neutrophil function n the transition period. Elevated BHBA 
is known to directly impair a number of functions of immune cells, including neutrophil 
migration, phagocytosis, and pathogen killing (Suriyasathaporn et al., 2000; Sartorelli et al., 
1999). Furthermore, as a marker of energy deficiency, greater concentrations of plasma BHBA 
likely indicate more severe negative energy balance, which is known to suppress immune 
function (Kimura et al., 1999; Goff and Horst, 1997). Together, the resulting immune deficiency 
would in turn promote retained placenta (Kimura et l., 2002). 
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Together, these data suggest that yeast product supplementation enhanced humoral and 
mucosal immunity, and modulated uterine inflammation and mammary gland health in transition 
dairy cows. Although the 30 g/d dose was sufficient to elicit most of these responses, given the 
numerical differences observed in the majority of immune function measures, together with the 
production and metabolism responses reported in the companion paper (Yuan et al., 2014), it 
seems that 60 g/d provided the most benefits to transition dairy cows. 
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Table 5-1 Primers used for RT-PCR detection of genes in the uterine tissue. 
 
Gene Accession Number1 
Forward primer 
Reverse primer 





IL-8      NM-173925 
GCTCTCTTGGCAGCTTTCCT 
GGCATCGAAGTTCTGTACTCATTCT 























1 From NCBI Entrez Nucleotide Database (http://www.ncbi.nlm.nih.gov/sites/entrez?db=nucleotide). 
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Table 5-2 Hematology and leukocyte differential during the experimental period. Values are least squares means ± SEM, n = 9-
10. 
 
 Treatment P value 
Item 0g 30g 60g 90g SEM Yeast vs. Control Linear Quadratic 
Hematology         
   Leukocyte count, 109 cells/L 12.0 11.2 12.0 10.9 1.17 0.63 0.64 0.91 
   Erythrocyte count, 1012 cells/L 5.94 5.76 5.82 5.82 0.12 0.33 0.59 0.47 
   Hemoglobin, g/dL 10.3 10.1 10.3 9.9 0.15 0.39 0.20 0.38 
   Hematocrit, % 30.7 30.0 30.4 29.0 0.46 0.10 0.03 0.43 
   Platelet count, 109 cells/L 204 260 264 243 25 0.04 0.09 0.27 
Leukocyte concentrations, 103 cells /µL 
   Neutrophils 4.26 3.66 3.65 3.43 0.28 0.05 0.06 0.51 
  Lymphocytes 5.54 5.36 6.22 5.46 0.96 0.90 0.89 0.76 
   Monocytes 1.74 1.73 1.84 1.66 0.22 0.99 0.90 0.70 
   Eosinophils 0.37 0.31 0.32 0.36 0.05 0.58 0.97 0.35 
   Basophils 0.006 0.005 0.006 0.005 0.001 0.47 0.44 0.80 
 176
Leukocyte fraction, % of total 
   Neutrophils 37.7 33.9 30.4 33.3 3.2 0.17 0.25 0.30 
   Lymphocytes 44.4 46.8 50.9 47.7 3.5 0.32 0.38 0.43 
   Monocytes 14.5 15.9 15.8 14.4 1.2 0.53 0.97 0.26 
   Eosinophils 3.43 2.97 2.91 3.68 0.52 0.69 0.76 0.24 




Table 5-3 Hematology and leukocyte differential with significant day effect (P < 0.05) during the experimental period. Values 
are least squares means ± SEM, n = 39-40. 
 
 Day1  
Item -21 -7 1 4 7 21 35 SEM 
Hematology         
   Leukocyte count, 109 cells/L 11.3ab 11.6b 12.8c 10.4a 11.1ab 11.5b 12.1bc 0.69 
   Erythrocyte count, 1012 
cells/L 
6.10d 6.07cd 6.16d 5.92c 5.76b 5.47a 5.37a 0.08 
   Hemoglobin, g/dL 10.7d 10.6d 10.8d 10.3c 10.1b 9.5a 9.2a 0.13 
   Hematocrit, % 31.6d 31.8de 32.7e 31.3d 29.9c 27.1b 26.0a 0.41 
   Platelet count, 109 cells/L 243b 180a 213ab 184a 207ab 349c 364c 23.5 
Leukocyte concentrations, 103 cells /µL       
   Neutrophils 3.37ab 4.19c 4.92d 2.76a 3.16ab 3.67bc 4.17c 0.28 
   Monocytes 1.13a 1.42a 1.87b 2.10b 1.84b 1.95b 1.92b 0.15 
   Lymphocytes 6.22c 5.53ab 5.45ab 5.27a 5.68b 5.63ab 5.72ab 0.51 
   Eosinophils 0.62d 0.60d 0.32c 0.24b 0.15a 0.20ab 0.27bc 0.04 
 178
Leukocyte fraction, % of total         
   Neutrophils 32.9bc 36.6cd 38.8d 27.3a 32.0b 33.6bc 35.5bd 2.04 
   Lymphocytes 51.1d 45.5ab 43.2a 49.3cd 49.5cd 47.5bc 46.0ab 4.22 
   Monocytes 10.3a 12.3a 14.9b 20.2c 16.9b 16.3b 15.2b 0.97 
   Eosinophils 5.66d 5.56d 3.00c 2.51bc 1.58a 2.00ab 2.43ac 0.41 
 
1 Days that do not share a common superscript are significantly different (P < 0.05). Pairwise differences were evaluated 
by the PDIFF option when the overall effect of day was significant. 
 
 




Table 5-4 Incidence of health disorders during the xperimental period. 
 
 Treatment1 
Disorder2 0g 30g 60g 90g 
Ketosis 1 3 1 1 
Retained Placenta 1 1 3 1 
Metritis 3 1 3 1 
Subclinical endometritis 1 3 2 2 
Clinical mastitis 2 1 0 1 
Displaced abomasum 0 1 0 1 
≥ 1 event  5 4 4 4 
 
1 There were no treatment effects (P > 0.10) on the incidence of any disorders. Yeast product was 
supplemented at 0, 30, 60, or 90 g/d to transition dairy cows from 21 d before expected calving 
to 42 d after calving. 
2 Ketosis was recorded when the urine ketone dipstick test (Ketostix; Bayer Corp. Diagnostics 
Division, Elkhart, IN) detected acetoacetate > 80 mg/dL on any day or > 40 mg/dL for 2 
consecutive days. Other health disorders were diagnosed according to the guidelines by Kelton et 
al. (1998).  
 
 
Figure 5-1 Milk SCS during the experimental period. 
30, 60, or 90 g/d to transition dairy cows from 21 d before expected calving to 42 d after calving. 
There was a week effect (P < 0.01), but no yeast 
0.53), or quadratic dose (P = 0.11) effects. There was a 
reflecting a tendency for quadratic dose effect on wk 1 (
wk 5 (P = 0.02). * indicates significant differences 
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Figure 5-2 Concentrations of IgG in colostrum samples collected immediately after calving
Yeast product was upplemented at 0, 30, 60, or 90 g/d to transition dairy cows from 21 d before 
expected calving to 42 d after calving. There were no yeast 
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Figure 5-3 Concentrations of plasma haptoglobin during the experimental period.
product was supplemented at 0, 30, 60, or 90 g/d to transitio  dairy cows from 21 d before 
expected calving to 42 d after calving.
control (P = 0.15), linear dose (P
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Figure 5-4 Killing capacity of heparinized 
E. coli strain during the experimental period. 
90 g/d to transition dairy cows from 21 d before exp c
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Figure 5-5 Plasma concentrations of 
relative to calving. Yeast product
cows from 21 d before expected 
7, and 14 with an ovalbumin. There was a tendency 
effect (P < 0.01), but no yeast product vs. control (
There was a treatment × day (P < 0.01) effect, reflecting that yeast product linearly increased 
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Figure 5-6 Concentrations of IgA in fecal samples collected on d 7 and 21 relative to 
calving. Yeast product was upplemented at 0, 30, 60, or 90 g/d to transition dairy cows from 21 
d before expected calving to 42 d after calving. There was a significant quadratic 
0.03), but no yeast product vs. control (
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Figure 5-7 Neutrophil populations of uterine samples collected on d 7 and 42 relative to 
calving. Yeast product was upplemented at 0, 30, 60, or 90 g/d to transition dairy cows from 21 
d before expected calving to 42 d after calving. (
0.53), linear dose (P = 0.69), quadratic 
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Figure 5-8 Relative mRNA abundance of inflammatory genes in uterine tissues collected on 
d 7 and 42 relative to calving. Yeast product 
transition dairy cows from 21 d before expected calving to
were day (P < 0.01) and quadratic
0.53), linear dose (P = 0.30), or treatment 
effect (P < 0.01), but no yeast product
dose (P = 0.77), or treatment × day
were day (P = 0.01) and linear dose 
0.20), quadratic dose (P = 0.54), or
elastase: There were day (P = 0.01), yeast 
0.03) effects, but no quadratic dose 
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Figure 5-9 Correlation between plasma haptoglobin concentrations on d 7 and 
populations of uterine samples 
or 90 g/d to transition dairy cows from 21 d before expected calving to 42 d after cal
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Figure 5-10 Comparison of neutrophil populations of uterine 
without retained placenta. Yeast product
dairy cows from 21 d before expected calving to 42 d after calving. 
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Chapter 6 - Overall Conclusions 
The transition from late gestation to early lactation is often the most problematic period 
in the production cycle of dairy cows. Cows experience dramatic nutrient and energy 
requirements for milk production, tremendous metabolic stress, and suppressed immune function. 
Inadequate adaptation to these changes often contributes to markedly elevated incidence of 
metabolic disorders and infectious diseases during this time. Increasing evidence suggests that 
elevated inflammation is common during the transition period. Unlike the classical inflammation 
associated with acute infection or tissue injury, the postpartum inflammatory state is low-grade 
and intertwined with metabolic function. This metabolic inflammation plays a key role in 
numerous disorders. An improved understanding of inflammatory pathways in transition cows 
may improve our ability to predict and prevent disorders.  
To mimic metabolic inflammation, we administered low amounts of a pro-inflammatory 
cytokine rbTNFα, to early lactation cows, and evaluated whether rbTNFα affects milk 
production, metabolism, and health (Chapter 2). We found that rbTNFα administration 
increased plasma concentrations of TNFα and haptoglobin, indicating increased systemic 
inflammation. Dry matter and water intake, milk yield, and milk fat and protein yields were all 
decreased by rbTNFα treatments by 15 to 18%. Administration of rbTNFα did not affect energy 
balance or markers of glucose and lipid metabolism, but increased the incidence of ketosis by 3-
fold in the first week of lactation. These data suggest that low-grade inflammation may impair 
production independent of altering systemic metabolism. Conversely, modulating this 
inflammation has the potential to improve productivity and health of dairy cows. 
To identify nutritional strategies that could modulate metabolism and immunity, we 
evaluated the efficacy of several feed supplements. I  Chapter 3, we evaluated effects of 
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chromium propionate, rumen-protected lysine and methionine, or both on metabolism, immune 
cell function, and adipocyte size in lactating cows. Our results showed that feeding these 
supplements for 35 d had minimal effects on metabolism or adipocyte size, but modulated 
immune function in lactation cows. Neutrophil inflammatory responses to pathogen-associated 
molecules may be enhanced by chromium supplementatio , and amino acids can also influence 
these responses in a parity-dependent manner.  
Supplementation of yeast products has been shown to impr ve production and 
metabolism, and enhance immune function particularly during physiological challenges. In 
Chapter 4, we determined whether supplementation of a yeast product to transition cows could 
modulate production, feeding behavior, and metabolism. We found that yeast product 
supplementation did not affect milk production and DMI, but modulated feeding behavior and 
metabolism. Specifically, we detected quadratic dose effects for prepartum feeding behavior, 
reflecting decreased meal size, meal length, and intermeal interval, and increased meal frequency 
for cows received 30 and 60 g/d of yeast products. The increase in meals consumed per day and 
decreased meal size may result in more consistent fe d intake and rumen fermentation patterns 
throughout the day. Although we found that treatments i creased plasma BHBA, it is unlikely 
that yeast product had a direct effect on lipid metabolism. In Chapter 5, we found that yeast 
product supplementation modulated immunity and uterine inflammatory signals in transition 
dairy cows. As a humoral immunity indicator, plasma anti-ovalbumin IgG production in 
response to ovalbumin vaccinations was linearly increased by yeast product. Treatments 
quadratically increased fecal IgA concentrations, suggesting that 30 and 60 g/d doses enhanced 
mucosal immunity. We also observed that supplementatio  of yeast product at 30 and 60 g/d 
decreased uterine IL-6 mRNA abundance, whereas the abundance of n utrophil myeloperoxidase 
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and elastase was linearly increased by treatments. Although yeast product exerted inconsistent 
effects on different uterine inflammatory signals and the implications are unclear, our findings 
nevertheless indicate that certain nutritional strategies are effective in modulating inflammation. 
There are many intriguing questions that would be valuable to explore in future research. 
Does immunosuppression in the transition period contribute to elevated inflammation, or vice 
versa? What is the prevalence and duration of metabolic inflammation in transition cows? What 
are the most important sources of metabolic inflammation in dairy cows? How does metabolic 
inflammation increase the risk of certain transition cow disorders? Does metabolic inflammation 
directly affect mammary gland function and subsequently milk synthesis? Given the necessary 
role of inflammation in normal physiological function, should we inhibit inflammation in early 
lactation? How can we help cows to strike a balance to promote a healthy degree of 
inflammation while minimize the pathological aspects of inflammation? What are the 
mechanisms underlying the modulatory effects of nutrien s (such as chromium and yeast 
products) on immunity? How to develop nutritional strategies that selectively inhibit excessive 
inflammation while enhancing immune function? 
Overall, a greater understanding of the role of metabolic inflammation in the transition 
period and the nutritional strategies that could modulate these signals may improve the 
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